Home The Word Brain My Amedeo FAQ Privacy About   


2049 Chinese

The 20K Word Road to Mandarin Proficiency

By B. S. Kamps et al.


  Otorhinolaryngology

  Free Subscription


Articles published in Oral Oncol

Retrieve available abstracts of 455 articles:
HTML format



Single Articles


    March 2024
  1. RUIZ-TORRES DA, Naegele S, Podury A, Wirth L, et al
    Immunotherapy time of infusion impacts survival in head and neck cancer: A propensity score matched analysis.
    Oral Oncol. 2024;151:106761.
    PubMed     Abstract available


  2. SIMON L, Paly J, Park E, Samuels-Kalow M, et al
    Medicare dental coverage for patients with head and neck cancer: An opportunity in need of advocates.
    Oral Oncol. 2024 Mar 15:106754. doi: 10.1016/j.oraloncology.2024.106754.
    PubMed    


  3. RICARDO ELIAS DE MELO P, Agra Monteiro M, Vitoria de Araujo Lopes N, Silva Cunha JL, et al
    Comment on "advancing oral cancer diagnosis in Brazil: Integrating artificial intelligence with Teledentistry for Better Patient Outcomes".
    Oral Oncol. 2024;151:106758.
    PubMed    


  4. RAJANATHADURAI J, Sindya J, Madar IH, Perumal E, et al
    Exosomal immune checkpoint protein (PD-L1): Hidden player in PD-1/PD-L1 blockade immunotherapy resistance in oral cancer.
    Oral Oncol. 2024;151:106748.
    PubMed    


  5. KIM DH, Lim ST, Kim HR, Kang EJ, et al
    Impact of PIK3CA and cell cycle pathway genetic alterations on durvalumab efficacy in patients with head and neck squamous cell carcinoma: Post hoc analysis of TRIUMPH study.
    Oral Oncol. 2024;151:106739.
    PubMed     Abstract available


  6. SANTANA LADM, Floresta LG, Alves EVM, Melo LMR, et al
    Advancing oral cancer diagnosis in Brazil: Integrating artificial intelligence with teledentistry for enhanced patient outcomes.
    Oral Oncol. 2024;151:106741.
    PubMed    


  7. CHEN K, Shi M, Mo S, Liu T, et al
    Clinical features and prognostic factors of nasopharyngeal carcinoma with brain metastases.
    Oral Oncol. 2024;151:106738.
    PubMed     Abstract available


  8. DING C, Dai DY, Luo ZK, Wang GY, et al
    Evaluation of a novel model incorporating serological indicators into the conventional TNM staging system for nasopharyngeal carcinoma.
    Oral Oncol. 2024;151:106725.
    PubMed     Abstract available


  9. LU X, Zhang JL, Zhai X, Liu Q, et al
    A case report on a nasal and oral cavity involving large solitary fibrous tumor and comprehensive review of case literature.
    Oral Oncol. 2024;150:106715.
    PubMed     Abstract available


  10. YOUNG RJ, Angel C, Bressel M, Pizzolla A, et al
    Characterising B cell expression and prognostic significance in human papillomavirus positive oropharyngeal cancer.
    Oral Oncol. 2024;150:106687.
    PubMed     Abstract available


    February 2024
  11. VAN SCHAIK JE, van der Vegt B, Slagter-Menkema L, van der Laan BFAM, et al
    Identification of new head and neck squamous cell carcinoma molecular imaging targets.
    Oral Oncol. 2024;151:106736.
    PubMed     Abstract available


  12. AHMED AA, Sborchia M, Bye H, Roman-Escorza M, et al
    Mutation detection in saliva from oral cancer patients.
    Oral Oncol. 2024;151:106717.
    PubMed     Abstract available


  13. CHEN QY, Guo SS, Luo Y, Qu S, et al
    Efficacy and safety of cadonilimab in previously treated recurrent or metastatic nasopharyngeal carcinoma(COMPASSION-06): A phase II multicenter study.
    Oral Oncol. 2024;151:106723.
    PubMed     Abstract available


  14. FANCELLO G, Jiang S, Licci G, Gallo O, et al
    Comments on the article titled "Factors associated with unknown primary status in head and neck squamous cell carcinoma": Is the N status the overlooked elephant in the room?
    Oral Oncol. 2024;151:106727.
    PubMed    


  15. HU J, Huang Q, Hu W, Liang F, et al
    Tumor volume instead of recurrent T category predicts clinical outcome of patients with locally recurrent nasopharyngeal carcinoma salvaged by carbon ion radiation therapy.
    Oral Oncol. 2024;151:106683.
    PubMed     Abstract available


  16. CABEZAS-CAMARERO S, Vazquez Masedo G, Puebla-Diaz F, Corona JA, et al
    Major and durable responses to photon and electron-beam palliative radiotherapies after immune-checkpoint inhibitors in head and neck cancer.
    Oral Oncol. 2024;150:106719.
    PubMed     Abstract available


  17. SANTANA NCM, de Sena ACVP, Rocha PADS, de Arruda JAA, et al
    Oral cancer and oral potentially malignant disorders in patients with Fanconi anemia - A systematic review.
    Oral Oncol. 2024;150:106699.
    PubMed     Abstract available


  18. BATTISTI A, Della Monaca M, Di Giorgio D, Priore P, et al
    Extranodal follicular dendritic cell sarcoma of the tonsil: An extremely rare clinical entity.
    Oral Oncol. 2024;149:106690.
    PubMed     Abstract available


  19. ADEN AA, Olawuni FO, Abdel-Halim CN, Zhu AQ, et al
    Association Between Social Determinants of Health, Distance from Treatment Center, and Treatment Type with Outcomes in Human Papillomavirus Associated Oropharyngeal cancer.
    Oral Oncol. 2024;149:106675.
    PubMed     Abstract available


  20. HEIRMAN AN, Dirven R, van der Molen L, Schreuder WH, et al
    The development of a decision aid for patients with operable oropharyngeal carcinoma in the Netherlands - A mixed methods study.
    Oral Oncol. 2024;149:106677.
    PubMed     Abstract available


  21. MEIRELLES DP, Da Costa AAS, Sousa-Neto SS, Cardoso SV, et al
    Methodological challenges in identifying histological prognostic markers for squamous cell carcinoma of the lip, mouth, and oropharynx.
    Oral Oncol. 2024;149:106665.
    PubMed    


  22. BALASAMY S, Sundramoorthy AK
    EGFR-targeted fluorescence imaging for precision margin assessment in oral cancer surgery.
    Oral Oncol. 2024;150:106712.
    PubMed    


    January 2024
  23. OCHOA SCUSSIATTO H, Stenson KM, Al-Khudari S, Jelinek MJ, et al
    Air pollution is associated with increased incidence-rate of head and neck cancers: A nationally representative ecological study.
    Oral Oncol. 2024;150:106691.
    PubMed     Abstract available


  24. LI L, Chen L, Fan M, Tian Y, et al
    A prospective, single-arm trial of PD-1 inhibitors plus chemoradiotherapy for solitary metachronous metastasis nasopharyngeal carcinoma.
    Oral Oncol. 2024;150:106695.
    PubMed     Abstract available


  25. STOGBAUER F, Otto R, Johrens K, Tinhofer I, et al
    Molecular subtyping of head and neck cancer - Clinical applicability and correlations with morphological characteristics.
    Oral Oncol. 2024;149:106678.
    PubMed     Abstract available


  26. JAGADEESHAN S, Suryamohan K, Shin N, Mathukkada S, et al
    Evolutionary dynamics of tipifarnib in HRAS mutated head and neck squamous cell carcinoma.
    Oral Oncol. 2024;149:106688.
    PubMed     Abstract available


  27. PUJOL A, Leon X, Holgado A, Valero C, et al
    External validation of the GETTEC algorithm for elective neck dissection in patients candidates for salvage total laryngectomy.
    Oral Oncol. 2024;149:106686.
    PubMed     Abstract available


  28. SHENKER RF, Razavian NB, D'Agostino RB Jr, Mowery YM, et al
    Clinical outcomes of oropharyngeal squamous cell carcinoma stratified by human papillomavirus subtype: A systematic review and meta-analysis.
    Oral Oncol. 2024;148:106644.
    PubMed     Abstract available


  29. COSTANTINO A, Sampieri C, Pace GM, Festa BM, et al
    Development of machine learning models for the prediction of long-term feeding tube dependence after oral and oropharyngeal cancer surgery.
    Oral Oncol. 2024;148:106643.
    PubMed     Abstract available


    December 2023
  30. TOPKAN E, Somay E, Selek U
    Comment on "A systematic review and meta-analysis of osteoradionecrosis following proton therapy in patients with head and neck cancer".
    Oral Oncol. 2023;149:106679.
    PubMed    


  31. AKHTAR A, Akhtar R, Nasir BM
    Response to "Integrating pretreatment MRI-detected nodal features and Epstein-Barr virus DNA to identify optimal candidates for intensity-modulated radiotherapy alone in patients with stage II nasopharyngeal carcinoma".
    Oral Oncol. 2023;149:106674.
    PubMed    


  32. SICHERO L, Goncalves MG, Bettoni F, Coser EM, et al
    Detection of serum biomarkers of HPV-16 driven oropharynx and oral cavity cancer in Brazil.
    Oral Oncol. 2023;149:106676.
    PubMed     Abstract available


  33. BILA M, Franken A, Van Dessel J, Garip M, et al
    Exploring long-term responses to immune checkpoint inhibitors in recurrent and metastatic head and neck squamous cell carcinoma.
    Oral Oncol. 2023;149:106664.
    PubMed     Abstract available


  34. GUO Y, Nakashima T, Cho BC, Lim DW, et al
    Clinical decision pathway and management of locally advanced head and neck squamous cell carcinoma: A multidisciplinary consensus in Asia-Pacific.
    Oral Oncol. 2023;148:106657.
    PubMed     Abstract available


  35. HUANG H, Chen Z, Zhu M, Deng X, et al
    Discontinuation and nonpublication of nasopharyngeal carcinoma clinical trials.
    Oral Oncol. 2023;148:106656.
    PubMed     Abstract available


  36. CHEN W, Yu X, Li H, Yuan S, et al
    Single-cell RNA-seq reveals MIF-(CD74 + CXCR4) dependent inhibition of macrophages in metastatic papillary thyroid carcinoma.
    Oral Oncol. 2023;148:106654.
    PubMed     Abstract available


  37. NEO J, Yip PL, Ong EHW, Miao J, et al
    Longitudinal post-radiotherapy plasma Epstein-Barr virus DNA trends inform on optimal risk stratification in endemic nasopharyngeal carcinoma.
    Oral Oncol. 2023;148:106655.
    PubMed     Abstract available


  38. WILLIAMSON A, Moen CM, Slim MAM, Warner L, et al
    Transoral robotic surgery without adjuvant therapy: A systematic review and meta-analysis of the association between surgical margins and local recurrence.
    Oral Oncol. 2023;147:106610.
    PubMed     Abstract available


  39. SILVA CUNHA JL
    Comment on "Decisional regret, symptom burden, and quality of life following transoral robotic surgery for oropharyngeal cancer".
    Oral Oncol. 2023;147:106626.
    PubMed    


  40. TIRELLI G, Boscolo-Rizzo P
    Palatoglossus muscle involvement in oropharynx Carcinoma: A pitfall in the T4 category definition of the 8th edition of the TNM staging system?
    Oral Oncol. 2023;147:106627.
    PubMed    


  41. BARROS EF, Cunha JLS, de Sousa DP, Pereira RVS, et al
    A destructive sinonasal organizing hematoma mimicking malignancy.
    Oral Oncol. 2023;147:106619.
    PubMed     Abstract available


    November 2023
  42. KALAVACHERLA S, Li V, Voora R, Victor M, et al
    Factors associated with unknown primary status in head and neck squamous cell carcinoma.
    Oral Oncol. 2023;148:106650.
    PubMed     Abstract available


  43. ZHANG S, Zheng M, Tian H, Liu W, et al
    Are immune checkpoint inhibitors ineffective in treating patients with head and neck squamous cell carcinoma aged 75 years or Older? A Meta-Analysis.
    Oral Oncol. 2023;148:106632.
    PubMed     Abstract available


  44. CHIU KW, Yu TP, Kao YS
    A systematic review and meta-analysis of osteoradionecrosis following proton therapy in patients with head and neck cancer.
    Oral Oncol. 2023;148:106649.
    PubMed     Abstract available


  45. DE SENA ACVP, de Arruda JAA, Felix FA, Tavares TS, et al
    Oral carcinoma in situ in a middle-aged woman with systemic sclerosis: Report of a rare case and literature review.
    Oral Oncol. 2023;148:106646.
    PubMed     Abstract available


  46. HES C, Desilets A, Tonneau M, El Ouarzadi O, et al
    Gut microbiome predicts gastrointestinal toxicity outcomes from chemoradiation therapy in patients with head and neck squamous cell carcinoma.
    Oral Oncol. 2023;148:106623.
    PubMed     Abstract available


  47. GAFFNEY J, Ramzan A, Dinizulu T, Maley C, et al
    Association of follow-up imaging frequency with temporal incidence and patterns of distant failure following (chemo) radiotherapy for HPV related oropharyngeal cancer.
    Oral Oncol. 2023;148:106645.
    PubMed     Abstract available


  48. CHEN AM, Harris JP, Tjoa T, Haidar Y, et al
    Racial disparities in the timely receipt of adjuvant radiotherapy for head and neck cancer.
    Oral Oncol. 2023;147:106611.
    PubMed     Abstract available


  49. TAKESHITA N, Enokida T, Okano S, Fujisawa T, et al
    Weekly paclitaxel, carboplatin and cetuximab (PCE) combination followed by nivolumab for recurrent and/or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN).
    Oral Oncol. 2023;147:106615.
    PubMed     Abstract available


  50. YU SM, Hsu CC, Hsueh SW, Hung CY, et al
    Frailty assessment by two screening instruments in non-elderly patients with head and neck cancer.
    Oral Oncol. 2023;147:106621.
    PubMed     Abstract available


  51. HARRINGTON KJ, Cohen EEW, Soulieres D, Dinis J, et al
    Pembrolizumab versus methotrexate, docetaxel, or cetuximab in recurrent or metastatic head and neck squamous cell carcinoma (KEYNOTE-040): Subgroup analysis by pattern of disease recurrence.
    Oral Oncol. 2023;147:106587.
    PubMed     Abstract available


  52. ABDEL-HALIM CN, O'Byrne TJ, Graves JP, Akpala CO, et al
    Patterns and distribution of regional nodal involvement and recurrence in a surgically treated oropharyngeal squamous cell carcinoma cohort at a tertiary center.
    Oral Oncol. 2023;146:106569.
    PubMed     Abstract available


  53. BARTEMES KR, Gochanour BR, Routman DM, Ma DJ, et al
    Assessing the capacity of methylated DNA markers of cervical squamous cell carcinoma to discriminate oropharyngeal squamous cell carcinoma in human papillomavirus mediated disease.
    Oral Oncol. 2023;146:106568.
    PubMed     Abstract available


  54. WARD MC, Wallander ML, Kuremsky JG, Dhakal R, et al
    Radiation therapy for cT1-2 carcinoma of the palatine tonsil diagnosed via a simple tonsillectomy: Dosimetry and patterns of care in the IMRT era.
    Oral Oncol. 2023;146:106557.
    PubMed     Abstract available


  55. KWON JJY, Liu AQ, Milner TD, Prisman E, et al
    Decisional regret, symptom burden, and quality of life following transoral robotic surgery for oropharyngeal cancer.
    Oral Oncol. 2023;146:106537.
    PubMed     Abstract available


  56. HERMSEN MA, Lechner M, Oliveira Ferrer L, Trama A, et al
    EUSICA/COST IMMUNO-model workshop fostering collaboration to advance sinonasal cancer research: A meeting report.
    Oral Oncol. 2023;146:106543.
    PubMed     Abstract available


  57. SARODE GS, Sarode SC, Sharma N
    Comment on "Clonal evolution of long-term expanding head and neck cancer organoid: Impact on treatment response for personalized therapeutic screening".
    Oral Oncol. 2023;147:106614.
    PubMed    


    October 2023
  58. ANSARI E, Ganry L, Van Cann EM, de Bree R, et al
    Impact of low skeletal muscle mass on postoperative complications in head and neck cancer patients undergoing free flap reconstructive surgery - A systematic review and meta-analysis.
    Oral Oncol. 2023;147:106598.
    PubMed     Abstract available


  59. LIU ZQ, Zhao YN, Wu YS, Zhang BY, et al
    Immunochemotherapy alone or immunochemotherapy plus subsequent locoregional radiotherapy in de novo metastatic nasopharyngeal carcinoma.
    Oral Oncol. 2023;147:106583.
    PubMed     Abstract available


  60. BATOOL S, Sethi RKV, Wang A, Dabekaussen K, et al
    Circulating tumor-tissue modified HPV DNA testing in the clinical evaluation of patients at risk for HPV-positive oropharynx cancer: The IDEA-HPV study.
    Oral Oncol. 2023;147:106584.
    PubMed     Abstract available


  61. SARAVANAN M, Sampath S, Arockiaraj J
    The use of advanced transoral robotic surgery in the treatment of oropharynx squamous cell carcinoma: A modern alternative for open surgery.
    Oral Oncol. 2023;145:106522.
    PubMed    


  62. TURNER MT, Chung J, Noorkbash S, Topf MC, et al
    Complications following salvage transoral robotic surgery with and without reconstruction: A systematic review of the literature.
    Oral Oncol. 2023;145:106467.
    PubMed     Abstract available


  63. ROBERTI E, Merlano M, Ravanelli M, Alberti A, et al
    Muscle quality and not quantity as a predictor of survival in head and neck squamous cell carcinoma.
    Oral Oncol. 2023;145:106540.
    PubMed     Abstract available


  64. REVERDY T, Varnier R, de Talhouet S, Duplomb S, et al
    Analysis of the benefit of salvage chemotherapy after progression on nivolumab in patients with squamous cell carcinoma of the head and neck.
    Oral Oncol. 2023;145:106533.
    PubMed     Abstract available


  65. KEMNADE JO, Florez M, Sabichi A, Zhang J, et al
    Phase I / II trial of metformin as a chemo-radiosensitizer in a head and neck cancer patient population.
    Oral Oncol. 2023;145:106536.
    PubMed     Abstract available


    September 2023
  66. SHAIKH MH, Dawson A, Prokopec SD, Barrett JW, et al
    Loss of LRP1B expression drives acquired chemo and radio-resistance in HPV-positive head and neck cancer.
    Oral Oncol. 2023;146:106580.
    PubMed     Abstract available


  67. CAVALIERI S, Platini F, Barretta F, Nuzzolese I, et al
    Pre-treatment risk factors to predict early cisplatin-related nephrotoxicity in locally advanced head and neck cancer patients treated with chemoradiation: A single Institution experience.
    Oral Oncol. 2023;146:106579.
    PubMed     Abstract available


  68. MALI SB
    Role of in vivo imaging in Head and Neck cancer management.
    Oral Oncol. 2023;146:106575.
    PubMed     Abstract available


  69. CHOI SY, Shim J, Gu DE, Kim SY, et al
    Clonal evolution of long-term expanding head and neck cancer organoid: Impact on treatment response for personalized therapeutic screening.
    Oral Oncol. 2023;146:106571.
    PubMed     Abstract available


  70. GUO J, He Y, Lin C, Jiang Q, et al
    Integrating pretreatment MRI-detected nodal features and Epstein-Barr virus DNA to identify optimal candidates for intensity-modulated radiotherapy alone in patients with stage II nasopharyngeal carcinoma.
    Oral Oncol. 2023;146:106574.
    PubMed     Abstract available


  71. SINGH R, Song S
    Clinical outcomes following observation, post-operative radiation therapy, or post-operative chemoradiation for HPV-associated oropharyngeal squamous cell carcinomas.
    Oral Oncol. 2023;146:106493.
    PubMed     Abstract available


  72. SHAH R, Tyagi S, Liu C, Judson B, et al
    Extra imaging beyond NCCN surveillance guidelines is cost effective for HPV- but not HPV+ oropharyngeal cancer.
    Oral Oncol. 2023;146:106564.
    PubMed    


  73. MANN JE, Smith JD, Kulkarni A, Foltin SK, et al
    Genome-wide open reading frame profiling identifies fibroblast growth factor signaling as a driver of PD-L1 expression in head and neck squamous cell carcinoma.
    Oral Oncol. 2023;146:106562.
    PubMed     Abstract available


  74. SAHA S, Patil VM, Noronha V, Menon N, et al
    Real world data on long term outcome of neoadjuvant chemotherapy in locally advanced esthesioneuroblastoma and sinonasal tumor with neuroendocrine differentiation - Results from a single centre study.
    Oral Oncol. 2023;144:106486.
    PubMed     Abstract available


  75. CANAHUATE G, Wentzel A, Mohamed ASR, van Dijk LV, et al
    Spatially-aware clustering improves AJCC-8 risk stratification performance in oropharyngeal carcinomas.
    Oral Oncol. 2023;144:106460.
    PubMed     Abstract available


    August 2023
  76. VIEIRA GS, Perin MY, Figueiredo-Maciel T, Risuenho AJG, et al
    Induction chemotherapy response of HPV-related multiphenotypic sinonasal carcinoma: First-ever reported therapeutic outcome and a brief literature review.
    Oral Oncol. 2023;146:106555.
    PubMed     Abstract available


  77. XU YC, Chen KH, Liang Y, Chen KQ, et al
    Efficacy of induction chemotherapy in lymph node-positive stage III nasopharyngeal carcinoma and identification of beneficiaries based on clinical features: A propensity score matching analysis.
    Oral Oncol. 2023;146:106554.
    PubMed     Abstract available


  78. TASOULAS J, Schrank TP, Smith BD, Agala CB, et al
    Time to treatment patterns of head and neck cancer patients before and during the Covid-19 pandemic.
    Oral Oncol. 2023;146:106535.
    PubMed     Abstract available


  79. CHARTERS E, Loy J, Wu R, Cheng K, et al
    Feasibility study of intensive intervention using novel trismus device during adjuvant radiation for head and neck cancer: Restorabite(TM).
    Oral Oncol. 2023;146:106558.
    PubMed    


  80. AL-MANEI K, Sobkowiak MJ, Nagadia RH, Heymann R, et al
    Mycobiota profile of oral fungal infections in head and neck cancer patients receiving radiotherapy: A 6-year retrospective MALDI-TOF mass spectrometry study.
    Oral Oncol. 2023;146:106556.
    PubMed     Abstract available


  81. ZHANG L, Liao Y
    Comment on: Efficacy of Anti-PD1 blockade in treating recurrent or metastatic nasopharyngeal cancer: A systematic review and meta-analysis.
    Oral Oncol. 2023;143:106435.
    PubMed    


  82. BHAMBHANI C, Sandford E, Haring CT, Brummel C, et al
    Development of a high-performance multi-probe droplet digital PCR assay for high-sensitivity detection of human papillomavirus circulating tumor DNA from plasma.
    Oral Oncol. 2023;143:106436.
    PubMed     Abstract available


    July 2023
  83. DOLL C, Bigus S, Hofmann E, Mrosk F, et al
    Sentinel lymph node biopsy in recurrent or secondary oral squamous cell carcinoma after previous neck dissection.
    Oral Oncol. 2023;145:106494.
    PubMed     Abstract available


  84. GAN M, Harris JP, Truong A, Nabar R, et al
    Timing of chemotherapy and radiation delivery for patients receiving chemoradiation for head and neck cancer: When does "concurrent" mean concurrent?
    Oral Oncol. 2023;145:106492.
    PubMed     Abstract available


  85. MULLER M, Li J, Giger R, Elicin O, et al
    Head and neck cancer with synchronous nodules of the lung as a diagnostic and therapeutic challenge - A systematic review.
    Oral Oncol. 2023;145:106529.
    PubMed     Abstract available


  86. WEI F, Fang R, Lyu K, Liao J, et al
    Exosomal PD-L1 derived from head and neck squamous cell carcinoma promotes immune evasion by activating the positive feedback loop of activated regulatory T cell-M2 macrophage.
    Oral Oncol. 2023;145:106532.
    PubMed     Abstract available


  87. WATSON E, El Maghrabi A, Lee JH, Pu J, et al
    Implication of dental insurance status on patterns of pre-radiation dental extraction and risk of osteoradionecrosis of the jaw in head-and-neck cancer patients.
    Oral Oncol. 2023;145:106527.
    PubMed     Abstract available


  88. NEWMAN S, Cowart JH, Omar N, Martin E, et al
    HPV-associated oropharyngeal Adenosquamous carcinoma with early metastatic disease detected by ctDNA.
    Oral Oncol. 2023;145:106526.
    PubMed     Abstract available


  89. HAN N, Zhou D, Ruan M, Yan M, et al
    Cancer cell-derived extracellular vesicles drive pre-metastatic niche formation of lymph node via IFNGR1/JAK1/STAT1-activated-PD-L1 expression on FRCs in head and neck cancer.
    Oral Oncol. 2023;145:106524.
    PubMed     Abstract available


  90. NGAMPHAIBOON N, Chairoungdua A, Dajsakdipon T, Jiarpinitnun C, et al
    Evolving role of novel radiosensitizers and immune checkpoint inhibitors in (chemo)radiotherapy of locally advanced head and neck squamous cell carcinoma.
    Oral Oncol. 2023;145:106520.
    PubMed     Abstract available


  91. WANG G, Dong Z, Huang C, Du X, et al
    The value of integrating tumor volume and plasma Epstein-Barr virus DNA load during sequential chemoradiotherapy for prognostic prediction and therapeutic guidance in high-risk locoregionally advanced nasopharyngeal carcinoma.
    Oral Oncol. 2023;145:106500.
    PubMed     Abstract available


  92. VIMALRAJ S, Sekaran S
    Exploring the potential of MiRNAs as predictive biomarkers for radioresistance in nasopharyngeal carcinoma.
    Oral Oncol. 2023;145:106521.
    PubMed    


  93. YOKOTA Y, Hasegawa T, Yamakawa N, Rin S, et al
    Comparison of the 8th edition of TNM staging of oral cancer with the 7th edition and its prognostic significance using clinical depth of invasion and extranodal extension.
    Oral Oncol. 2023;145:106519.
    PubMed     Abstract available


  94. KO K, Takahashi T, Honda K, Horii A, et al
    Avoiding total thyroidectomy for ectopic papillary thyroid carcinoma arising from the lateral neck.
    Oral Oncol. 2023;145:106501.
    PubMed    


  95. LI D, Li C, Shi S
    Letter to the editor: The efficacy and safety of VEGF/VEGFR inhibitors in patients with recurrent or metastatic nasopharyngeal carcinoma.
    Oral Oncol. 2023;145:106497.
    PubMed    


  96. PENG WS, Xing X, Li YJ, Ding JH, et al
    Prognostic nomograms for nasopharyngeal carcinoma with nodal features and potential indication for N staging system: Validation and comparison of seven N stage schemes.
    Oral Oncol. 2023;144:106438.
    PubMed     Abstract available


  97. ZENGA J, Awan M, Hadi Razeghi Kondelaji M, Hansen C, et al
    Photoactivated HPPH-Liposomal therapy for the treatment of HPV-Negative head and neck cancer.
    Oral Oncol. 2023;144:106487.
    PubMed     Abstract available


  98. CHEPEHA DB, Esemezie AO, Philteos J, Brown DH, et al
    Glossectomy for the treatment of oral cavity carcinoma: Quantitative, functional and patient-reported quality of life outcomes differ by four glossectomy defects.
    Oral Oncol. 2023;142:106431.
    PubMed     Abstract available


  99. EVERTON ASSUNCAO RIBEIRO DA CO, Luz Santos I, Julia Andrade Pereira Soares M, Dos Reis de Paula I, et al
    A case of metastatic NUT carcinoma of the nasal cavity.
    Oral Oncol. 2023;142:106432.
    PubMed    


    June 2023
  100. HE M, Gouda M, Gires O
    EpCAM and EGFR crosstalk in the development of resistance towards Cetuximab treatment in head and neck cancer.
    Oral Oncol. 2023;143:106465.
    PubMed    


  101. YEUNG C, Meyers BM, Kartolo A
    Management of metastatic head and neck Cancer: An all-in, kitchen-sink Approach?
    Oral Oncol. 2023;143:106444.
    PubMed    


  102. KOYUNCU CF, Frederick MJ, Thompson LDR, Corredor G, et al
    Machine learning driven index of tumor multinucleation correlates with survival and suppressed anti-tumor immunity in head and neck squamous cell carcinoma patients.
    Oral Oncol. 2023;143:106459.
    PubMed     Abstract available


  103. PANDIAR D, Nayanar SK, Nair V
    Papillary thyroid carcinoma arising in thyroglossal duct cyst: A case report with long term follow-up.
    Oral Oncol. 2023;143:106439.
    PubMed    


    May 2023
  104. UMEMORI K, Ono K, Eguchi T, Kawai H, et al
    EpEX, the soluble extracellular domain of EpCAM, resists cetuximab treatment of EGFR-high head and neck squamous cell carcinoma.
    Oral Oncol. 2023;142:106433.
    PubMed     Abstract available


  105. HIGGINSON JA, Breik O, Thompson AH, Ashrafian H, et al
    Diagnostic accuracy of intraoperative margin assessment techniques in surgery for head and neck squamous cell carcinoma: A meta-analysis.
    Oral Oncol. 2023;142:106419.
    PubMed     Abstract available


  106. WARNAKULASURIYA S
    "Textbook outcome" as a quality metric of care in predicting survival from oral cancer.
    Oral Oncol. 2023;141:106416.
    PubMed    


  107. DING H, Wu C, Sun W, Zhan Q, et al
    NUDT5-Determines the fate of head and neck squamous cell carcinoma cells under endoplasmic reticulum stress by catalyzing nuclear ATP production to promote DNA repair.
    Oral Oncol. 2023;141:106397.
    PubMed     Abstract available


  108. WANG Y, Gao Y, Yuan L, Zhang J, et al
    Retraction notice to "Psychological needs and associated factors among perioperative patients with oral cancer" [Oral Oncol. 123 (2021) 105615].
    Oral Oncol. 2023 May 5:106394. doi: 10.1016/j.oraloncology.2023.106394.
    PubMed    


  109. RETTIG EM, Waterboer T, Sim E, Faden DL, et al
    Relationship of HPV16 E6 seropositivity with circulating tumor tissue modified HPV16 DNA before head and neck cancer diagnosis.
    Oral Oncol. 2023;141:106417.
    PubMed    


    April 2023
  110. MISRA SR, Mohapatra SSG, Das R
    Comment on "Elective neck dissection: Desideratum or overkill?".
    Oral Oncol. 2023;141:106403.
    PubMed    


  111. HUE J, Valinciute Z, Thavaraj S, Veschini L, et al
    Multifactorial estimation of clinical outcome in HPV-associated oropharyngeal squamous cell carcinoma via automated image analysis of routine diagnostic H&E slides and neural network modelling.
    Oral Oncol. 2023;141:106399.
    PubMed     Abstract available


  112. BOSCOLO-RIZZO P, Tirelli G, Polesel J, Sia E, et al
    TERT promoter mutations in head and neck squamous cell carcinoma: A systematic review and meta-analysis on prevalence and prognostic significance.
    Oral Oncol. 2023;140:106398.
    PubMed     Abstract available


  113. YANG TH, Xirasagar S, Cheng YF, Chen CS, et al
    Trends in the incidence of head and neck cancer: A nationwide population-based study.
    Oral Oncol. 2023;140:106391.
    PubMed     Abstract available


  114. MERCHANT YP, Shah A
    Elective neck dissection: Desideratum or overkill?
    Oral Oncol. 2023;140:106389.
    PubMed    


  115. ARAUJO ALD, Moraes MC, Perez-de-Oliveira ME, Silva VMD, et al
    Machine learning for the prediction of toxicities from head and neck cancer treatment: A systematic review with meta-analysis.
    Oral Oncol. 2023;140:106386.
    PubMed     Abstract available


  116. PATEL ND, Cabrera CI, Fowler NM, Li S, et al
    Incidence and medical complications of COVID-19 in the total laryngectomy population: A population-based study.
    Oral Oncol. 2023;139:106353.
    PubMed     Abstract available


  117. COMER JC, Harris AB, Hess AO, Hitchcock KE, et al
    Does lymphovascular invasion predict survival in oral cancer? A population-based analysis.
    Oral Oncol. 2023;140:106387.
    PubMed     Abstract available


    March 2023
  118. ZUO N, Ma L, Liu T, Hu W, et al
    Human papillomavirus associated XPF deficiency increases alternative end joining and cisplatin sensitivity in head and neck squamous cell carcinoma.
    Oral Oncol. 2023;140:106367.
    PubMed     Abstract available


  119. SAMPIERI C, Costantino A, Pirola F, Kim D, et al
    Neoadjuvant chemotherapy combined with transoral robotic surgery for stage III and IV laryngeal and hypopharyngeal carcinomas.
    Oral Oncol. 2023;140:106371.
    PubMed     Abstract available


  120. HERNANDO-CALVO A, Mirallas O, Marmolejo D, Saavedra O, et al
    Nutritional status associates with immunotherapy clinical outcomes in recurrent or metastatic head and neck squamous cell carcinoma patients.
    Oral Oncol. 2023;140:106364.
    PubMed     Abstract available


  121. CHIEN CY, Wang CP, Lee LY, Lee SR, et al
    Indications for elective neck dissection in cT1N0M0 oral cavity cancer according to the AJCC eight edition: A nationwide study.
    Oral Oncol. 2023;140:106366.
    PubMed     Abstract available


  122. LAMBERT T, Tasoulas J, Flores M, Sheth S, et al
    Circulating tumor HPV DNA as an alternative method to determine HPV status in oropharyngeal squamous cell carcinoma.
    Oral Oncol. 2023;140:106361.
    PubMed     Abstract available


  123. SCHEFF NN, Nilsen ML, Li J, Harris AL, et al
    The effect of opioids on the efficacy of immunotherapy in recurrent/metastatic squamous cell carcinoma of the head and neck.
    Oral Oncol. 2023;140:106363.
    PubMed     Abstract available


  124. BANOUB RG, Crippen MM, Fiorella MA, Ross HM, et al
    Variance in 3D anatomic localization of surgical margins based on conventional margin labeling in head and neck squamous cell carcinoma.
    Oral Oncol. 2023;139:106360.
    PubMed     Abstract available


  125. ZHANG L, Freeman T, Sun S, Bhateja P, et al
    The use of plasma circulating tumor DNA for early detection of oligometastatic disease in HPV positive oropharyngeal squamous cell carcinoma.
    Oral Oncol. 2023;139:106357.
    PubMed    


  126. DE FELICE F
    Docetaxel plus radiotherapy for head and neck cancer.
    Oral Oncol. 2023;139:106359.
    PubMed    


  127. ECONOMOPOULOU P, Spathis A, Kotsantis I, Maratou E, et al
    Next-generation sequencing (NGS) profiling of matched tumor and circulating tumor DNA (ctDNA) in head and neck squamous cell carcinoma (HNSCC).
    Oral Oncol. 2023;139:106358.
    PubMed     Abstract available


  128. DE SOUSA LG, Lazar Neto F, Dal Lago EA, Sikora A, et al
    Human papillomavirus status and prognosis of oropharyngeal high-grade neuroendocrine carcinoma.
    Oral Oncol. 2023;138:106311.
    PubMed     Abstract available


    February 2023
  129. LI SC, Deng SW, Sun XS, Lan KQ, et al
    A new prognostic model for predicting outcomes of patients with recurrent or metastatic nasopharyngeal carcinoma receiving subsequent line (>/=2 lines) anti-programmed death-1 monotherapy.
    Oral Oncol. 2023;139:106336.
    PubMed     Abstract available


  130. GUERLAIN J, Marhic A, Casiraghi O, Lumbroso J, et al
    Occult nodal metastases in T1-T2cN0 oral squamous cell carcinoma: Correlation between sentinel node positivity and completion neck dissection analysis.
    Oral Oncol. 2023;139:106338.
    PubMed     Abstract available


  131. PARIKH AS, Yu VX, Flashner S, Okolo OB, et al
    Patient-derived three-dimensional culture techniques model tumor heterogeneity in head and neck cancer.
    Oral Oncol. 2023;138:106330.
    PubMed     Abstract available


  132. XIAO Y, Mao L, Yang QC, Wang S, et al
    CD103 blockade impair anti-CTLA-4 immunotherapy in oral cancer.
    Oral Oncol. 2023;138:106331.
    PubMed     Abstract available


  133. RYGALSKI CJ, Huttinger ZM, Zhao S, Brock G, et al
    High surgical volume is associated with improved survival in head and neck cancer.
    Oral Oncol. 2023;138:106333.
    PubMed     Abstract available


  134. BALLAL Y, Gete M, Su J, O'Sullivan B, et al
    The collateral impact of the COVID-19 pandemic on HPV-positive oropharyngeal cancer diagnosis.
    Oral Oncol. 2023;138:106332.
    PubMed     Abstract available


  135. BOOT PA, Mes SW, de Bloeme CM, Martens RM, et al
    Magnetic resonance imaging based radiomics prediction of Human Papillomavirus infection status and overall survival in oropharyngeal squamous cell carcinoma.
    Oral Oncol. 2023;137:106307.
    PubMed     Abstract available


    January 2023
  136. VAN BEERS MA, Schreuder WH, Balm AJM, van Dijk BAC, et al
    Is locally advanced head and neck cancer 'increasing' in the Netherlands? The paradox of absolute numbers, standardized incidence rates and proportional share.
    Oral Oncol. 2023;138:106316.
    PubMed     Abstract available


  137. PELLET A, Bertolus C, Saintigny P, Foy JP, et al
    Reliability of gene-expression profiling from tumor biopsy for refining neoadjuvant strategies in patients with head and neck squamous cell carcinoma.
    Oral Oncol. 2023;138:106310.
    PubMed     Abstract available


  138. ROBBINS Y, Friedman J, Redman J, Sievers C, et al
    Tumor cell HLA class I expression and pathologic response following neoadjuvant immunotherapy for newly diagnosed head and neck cancer.
    Oral Oncol. 2023;138:106309.
    PubMed     Abstract available


  139. WINNAND P, Ooms M, Heitzer M, Lammert M, et al
    Real-time detection of bone-invasive oral cancer with laser-induced breakdown spectroscopy: A proof-of-principle study.
    Oral Oncol. 2023;138:106308.
    PubMed     Abstract available


  140. WU Z, Han Y, Wan Y, Hua X, et al
    Oral microbiome and risk of incident head and neck cancer: A nested case-control study.
    Oral Oncol. 2023;137:106305.
    PubMed     Abstract available


  141. ARGYRIS PP, Saavedra F, Malz C, Stone IA, et al
    Intracellular calprotectin (S100A8/A9) facilitates DNA damage responses and promotes apoptosis in head and neck squamous cell carcinoma.
    Oral Oncol. 2023;137:106304.
    PubMed     Abstract available


  142. YEO BSY, Song HJJMD, Soong YL, Chua MLK, et al
    Efficacy of Anti-PD1 Blockade in Treating Recurrent or Metastatic Nasopharyngeal Cancer: A Systematic Review and Meta-analysis.
    Oral Oncol. 2023;136:106242.
    PubMed     Abstract available


  143. ADEOYE J, Zheng LW, Thomson P, Choi SW, et al
    Explainable ensemble learning model improves identification of candidates for oral cancer screening.
    Oral Oncol. 2023;136:106278.
    PubMed     Abstract available


    December 2022
  144. IDA S, Takahashi H, Tada H, Mito I, et al
    Dynamic changes of the EMT spectrum between circulating tumor cells and the tumor microenvironment in human papillomavirus-positive head and neck squamous cell carcinoma.
    Oral Oncol. 2022;137:106296.
    PubMed     Abstract available


  145. GHEENA S, Ezhilarasan D
    Personalized mRNA cancer vaccines with immune checkpoint inhibitors: A promising therapeutic approach in oral cancer patients.
    Oral Oncol. 2022;137:106282.
    PubMed    


  146. DE FELICE F, Bossi P
    Pembrolizumab with or without chemotherapy in recurrent or metastatic head and neck squamous cell carcinoma: Hypothesis coming from the subgroup analysis.
    Oral Oncol. 2022;137:106275.
    PubMed    


  147. PERES MA, Huihua L, Antunes JLF, Perea LME, et al
    Time trend and Age-Period-Cohort analysis of potentially HPV-related oral and pharyngeal cancer incidence in Singapore between 1968 and 2017.
    Oral Oncol. 2022;136:106272.
    PubMed     Abstract available


  148. TAZEEN S, Suri H, Lakshmi R, Subash A, et al
    Swallowing: A delayed milestone post-surgery in tongue cancers.
    Oral Oncol. 2022;135:106238.
    PubMed     Abstract available


  149. TAVERNA F, Alfieri S, Rebecca R, Giulia C, et al
    Comparing BamHI-W and CE-marked assays to detect circulating Epstein-Barr Virus (EBV) DNA of nasopharyngeal cancer patients in a non-endemic area.
    Oral Oncol. 2022;135:106229.
    PubMed     Abstract available


  150. GUNAWARDENA DA, Howes D, Fleming S, Clark J, et al
    Reconstruction of a maxillectomy and rhinectomy defect utilising a novel subperiosteal prosthesis and magnet-retained nasal prosthesis: A case report.
    Oral Oncol. 2022;135:106222.
    PubMed    


  151. TAPIA M, Manji J, Dhillon K, Kleid S, et al
    The negative predictive value of FDG PET/CT staging in early oropharyngeal squamous cell carcinoma and implications to transoral robotic surgery patient selection.
    Oral Oncol. 2022;135:106213.
    PubMed     Abstract available


    November 2022
  152. MITO I, Takahashi H, Kawabata-Iwakawa R, Horikawa M, et al
    Tumor-derived exosomes elicit cancer-associated fibroblasts shaping inflammatory tumor microenvironment in head and neck squamous cell carcinoma.
    Oral Oncol. 2022;136:106270.
    PubMed     Abstract available


  153. KIRAN NAZEER P, Shaheen S, Shafique K, Sarfraz A, et al
    The role of precision medicine in head and neck cancer: A systematic study of ongoing clinical trials.
    Oral Oncol. 2022;136:106271.
    PubMed    


  154. PENG Y, Liu Y, Shen G, Chen Z, et al
    Improved accuracy of auto-segmentation of organs at risk in radiotherapy planning for nasopharyngeal carcinoma based on fully convolutional neural network deep learning.
    Oral Oncol. 2022;136:106261.
    PubMed     Abstract available


  155. MANZOOR H, Rasheed A, Zeen F, Sarfraz A, et al
    Anti-PD-1 immunotherapy - Pembrolizumab current clinical trials for advanced head and neck cancer: A mapping systematic study.
    Oral Oncol. 2022;136:106266.
    PubMed    


  156. LIU HC, Williamson CW, Zou J, Todd JR, et al
    Quantitative prediction of aspiration risk in head and neck cancer patients treated with radiation therapy.
    Oral Oncol. 2022;136:106247.
    PubMed     Abstract available


  157. CHAN JYK, Cheung MK, Lan L, Ng C, et al
    Characterization of oral microbiota in HPV and non-HPV head and neck squamous cell carcinoma and its association with patient outcomes.
    Oral Oncol. 2022;135:106245.
    PubMed     Abstract available


  158. KMIECIK M, Nogal P, Banaszewski J, Wierzbicka M, et al
    Corrigendum to "Anterolateral thigh free flap reconstruction of pharyngoesophageal defect caused by radiotherapy for laryngeal cancer: A case report" [Oral Oncol. 134 (2022) 106135].
    Oral Oncol. 2022 Nov 4:106233. doi: 10.1016/j.oraloncology.2022.106233.
    PubMed    


  159. QUAN T, Guan W, Huang W, Cui C, et al
    Carotid space involvement is a prognostic factor and marker for induction chemotherapy in patients with nasopharyngeal carcinoma.
    Oral Oncol. 2022;135:106230.
    PubMed     Abstract available


  160. BISHESHAR SK, van der Kamp MF, de Ruiter EJ, Ruiter LN, et al
    The prognostic role of tumor associated macrophages in squamous cell carcinoma of the head and neck: A systematic review and meta-analysis.
    Oral Oncol. 2022;135:106227.
    PubMed     Abstract available


  161. CHIDAMBARAM S, Hong SA, Simpson MC, Osazuwa-Peters N, et al
    Temporal trends in oropharyngeal cancer incidence, survival, and cancer-directed surgery among elderly Americans.
    Oral Oncol. 2022;134:106132.
    PubMed     Abstract available


  162. AROSIO AD, Bernasconi DP, Valsecchi MG, Pacifico C, et al
    Patterns of recurrences in sinonasal cancers undergoing an endoscopic surgery-based treatment: Results of the MUSES* on 940 patients: *MUlti-institutional collaborative Study on Endoscopically treated Sinonasal cancers.
    Oral Oncol. 2022;134:106123.
    PubMed     Abstract available


  163. MANJUSHA M, Saravanan M
    Oropharyngeal cancer associated with sarcopenic obesity and sarcopenic weight loss.
    Oral Oncol. 2022;134:106101.
    PubMed    


  164. FITZGERALD CWR, Davies JC, de Almeida JR, Rich JT, et al
    Factors predicting pharyngocutaneous fistula in patients after salvage laryngectomy for laryngeal malignancy - A multicenter collaborative cohort study.
    Oral Oncol. 2022;134:106089.
    PubMed     Abstract available


  165. DE LUCA P, Scarpa A, Viola P, Motta G, et al
    Collision tumors of the larynx: A retrospective single-center case series of an extremely rare phenomenon.
    Oral Oncol. 2022;134:106096.
    PubMed    


  166. WEINBERGER JM, Abd El Qadir N, Hirshoren N
    Double trouble: A cohort study of re-irradiation and laryngectomy - Severity of and risk for pharyngocutaneous fistula.
    Oral Oncol. 2022;134:106069.
    PubMed     Abstract available


  167. DE BREE R, Leemans CR
    When to perform a paratracheal lymph node dissection during total laryngectomy?
    Oral Oncol. 2022;134:106048.
    PubMed    


  168. WU B, Shen L, Peng G, Li Y, et al
    Molecular characteristics of pediatric nasopharyngeal carcinoma using whole-exome sequencing.
    Oral Oncol. 2022;135:106218.
    PubMed     Abstract available


  169. HUANG J, Harris E, Lorch J
    Vaccination as a therapeutic strategy for Nasopharyngeal carcinoma.
    Oral Oncol. 2022;135:106083.
    PubMed     Abstract available


    October 2022
  170. XUE S, Song G, Zhu Y, Zhang N, et al
    The efficacy and safety of VEGF/VEGFR inhibitors in patients with recurrent or metastatic nasopharyngeal carcinoma: A meta-analysis.
    Oral Oncol. 2022;135:106231.
    PubMed     Abstract available


  171. KAO DD, Ferrandino RM, Bauml JM, Marshall DC, et al
    Prophylactic feeding tube placement for squamous cell carcinoma of the head and neck.
    Oral Oncol. 2022;135:106216.
    PubMed     Abstract available


  172. ZHU L, Li M, Tang G, Shi L, et al
    Role of salivary miRNAs as noninvasive biomarkers in head and neck squamous cell carcinomas and oral potentially malignant disorders - Reply.
    Oral Oncol. 2022;135:106224.
    PubMed    


  173. DENNIS MJ, Sacco AG, Qi Y, Bykowski J, et al
    A phase I study of avelumab, palbociclib, and cetuximab in patients with recurrent or metastatic head and neck squamous cell carcinoma.
    Oral Oncol. 2022;135:106219.
    PubMed     Abstract available


  174. GOVINDARASU M, Prathap L, Govindasamy R
    Histone deacetylase inhibitors regulate the oral cancer via PI3K/AKT signaling pathway.
    Oral Oncol. 2022;135:106221.
    PubMed    


  175. CHABRILLAC E, Lebars S, Breuskin I, Thariat J, et al
    Pregnancy-associated head and neck cancer:a partnership between theCORASSO patient association and theREFCOR physician networkto study a pathology of extremely rare occurrence.
    Oral Oncol. 2022;135:106223.
    PubMed    


  176. OLAWUNI FO, Sauer AB, Daher GS, Douse DM, et al
    The reporting and representation of sex and gender in head and neck cancer clinical trials.
    Oral Oncol. 2022;135:106217.
    PubMed    


  177. SUNDRAMOORTHY AK, Atchudan R, Arya S
    Utilization of Raman spectroscopy in biochemical fingerprint analysis for oral cancer screening and diagnosis.
    Oral Oncol. 2022;135:106192.
    PubMed    


  178. ZHU L, Deng Y, Ji T, Zhou H, et al
    Metformin and oral cancer: In reply with emphasis on an emerging role of an old drug in oral cancer chemoprevention.
    Oral Oncol. 2022;135:106196.
    PubMed    


  179. MANJUSHA M, Saravanan M
    Development of novel electrochemical based nano-biosensors for the diagnosis of oral potentially malignant disorders and oral carcinoma.
    Oral Oncol. 2022;135:106197.
    PubMed    


  180. SEKAR AA, Veeraraghavan VP, Raj AT, Patil S, et al
    Unravelling the long non-coding RNA, CYTOR can serve as a potential therapeutic target in oral cancer.
    Oral Oncol. 2022;135:106195.
    PubMed    


  181. GURMEET SINGH A, Sathe P, Roy S, Thiagrajan S, et al
    Incidence and impact of skip metastasis in the neck in early oral cancer: Reality or a myth?
    Oral Oncol. 2022;135:106201.
    PubMed     Abstract available


  182. KRISHNAMOORTHY K, Priya Veeraraghavan V, Jayaraman S
    E3 ubiquitin ligases: A therapeutic drug target in head and neck squamous cell carcinoma.
    Oral Oncol. 2022;135:106193.
    PubMed    


  183. ZHU S, Zhang F, Zhao G, Zhang X, et al
    Trends in the global burden of oral cancer joint with attributable risk factors: Results from the global burden of disease study 2019.
    Oral Oncol. 2022;134:106189.
    PubMed     Abstract available


  184. LIU W, Ji T, Zhang C, Zhou Q, et al
    Cell-free DNA hypermethylated genes may have a limited role in cancer screening but a potential role in risk assessment of head and neck cancer.
    Oral Oncol. 2022;134:106129.
    PubMed     Abstract available


  185. HENG Y, Yang Z, Lin J, Liu Q, et al
    Risks of central lymph node metastasis in papillary thyroid carcinoma with or without multifocality in at least one lobe: A multi-center analysis.
    Oral Oncol. 2022;134:106185.
    PubMed     Abstract available


    September 2022
  186. MORSE RT, Beaty B, Scanga L, Blumberg J, et al
    Diagnostic accuracy of FNA to determine HPV status in HPV-associated oropharyngeal squamous cell carcinoma.
    Oral Oncol. 2022;134:106131.
    PubMed     Abstract available


  187. ZHU GL, Fang XL, Yang KB, Tang LL, et al
    Development and validation of a joint model for dynamic prediction of overall survival in nasopharyngeal carcinoma based on longitudinal post-treatment plasma cell-free Epstein-Barr virus DNA load.
    Oral Oncol. 2022;134:106140.
    PubMed     Abstract available


  188. XUE F, Ou D, Ou X, Zhou X, et al
    Long-term results of the phase II dose and volume de-escalation trial for locoregionally advanced nasopharyngeal carcinoma.
    Oral Oncol. 2022;134:106139.
    PubMed     Abstract available


  189. SANKAR S
    New insights into CAR T-cell therapy for recurrent head and neck squamous cell carcinoma.
    Oral Oncol. 2022;134:106137.
    PubMed    


  190. KMIECIK M, Nogal P, Wierzbicka M, Jackowska J, et al
    Anterolateral thigh free flap reconstruction of pharyngoesophageal defect caused by radiotherapy for laryngeal cancer: A case report.
    Oral Oncol. 2022;134:106135.
    PubMed     Abstract available


  191. GUPTA T, Kannan S, Ghosh-Laskar S, Agarwal JP, et al
    Concurrent chemoradiotherapy with cisplatin given once-a-week versus every-three weekly in head and neck squamous cell carcinoma: Non-inferior, equivalent, or superior?
    Oral Oncol. 2022;134:106130.
    PubMed     Abstract available


  192. HITT R, Mesia R, Lozano A, Iglesias Docampo L, et al
    Randomized phase 3 noninferiority trial of radiotherapy and cisplatin vs radiotherapy and cetuximab after docetaxel-cisplatin-fluorouracil induction chemotherapy in patients with locally advanced unresectable head and neck cancer.
    Oral Oncol. 2022;134:106087.
    PubMed     Abstract available


  193. ZHANG J, Wu HY, Lu Q, Shan XF, et al
    Effects of personalized swallowing rehabilitation in patients with oral cancer after free flap transplantation: A cluster randomized controlled trial.
    Oral Oncol. 2022;134:106097.
    PubMed     Abstract available


  194. PATIL V, Kumar S, Noronha V, Menon N, et al
    Long term outcomes of a randomized controlled clinical trial comparing the efficacy of Cabazitaxel versus docetaxel as second-line or above therapy in recurrent head and neck cancer.
    Oral Oncol. 2022;134:106085.
    PubMed    


  195. SARODE GS, Anand R, Sharma NK, Sarode SC, et al
    Hot and cold tumor: Recent developments and perspectives on oral cancer.
    Oral Oncol. 2022;134:106114.
    PubMed    


  196. BEOM HEO D, Piao Y, Hee Lee J, Ju SH, et al
    Completion thyroidectomy may not be required for papillary thyroid carcinoma with multifocality, lymphovascular invasion, extrathyroidal extension to the strap muscles, or five or more central lymph node micrometastasis.
    Oral Oncol. 2022;134:106115.
    PubMed     Abstract available


  197. SAHNI V, Kumar A, Gupta S, Sharma S, et al
    Metformin and oral cancer.
    Oral Oncol. 2022;134:106125.
    PubMed    


  198. TOBIAS MAS, Nogueira BP, Santana MCS, Pires RG, et al
    Artificial intelligence for oral cancer diagnosis: What are the possibilities?
    Oral Oncol. 2022;134:106117.
    PubMed     Abstract available


  199. SHREE HARINI K, Ezhilarasan D, Elumalai P
    Restoring the anti-tumor property of PTEN: A promising oral cancer treatment.
    Oral Oncol. 2022;134:106113.
    PubMed    


  200. NONG T, Medrano T, Marrero C, Rubens M, et al
    Radiation induced taste changes in head and neck cancer - differential impact of treatment factors.
    Oral Oncol. 2022;134:106105.
    PubMed    


  201. MUTHUKRISHNAN L
    "TGM3 - A novel biomarker as a potential diagnostic target for head and neck squamous cell carcinoma (HNSCC)".
    Oral Oncol. 2022;134:106118.
    PubMed    


  202. MONY U, Priya Veeraraghavan V
    "Rules" to the genetic progression of tumours deciphered: Is it time to think differently in treating oral cancer patients?
    Oral Oncol. 2022;134:106111.
    PubMed    


  203. PRASAD M, Jayaraman S, Rajagopal P, Veeraraghavan VP, et al
    Apoptosis regulating CircRNAs: Emerging role in oral cancer therapeutics.
    Oral Oncol. 2022;134:106107.
    PubMed    


  204. DE WIT JG, van Schaik JE, Voskuil FJ, Vonk J, et al
    Comparison of narrow band and fluorescence molecular imaging to improve intraoperative tumour margin assessment in oral cancer surgery.
    Oral Oncol. 2022;134:106099.
    PubMed     Abstract available


  205. VILASECA I, Xavier Aviles-Jurado F, Lehrer E, Valduvieco I, et al
    CO2-TOLMS for laryngeal cancer in the elderly, pushing the boundaries of partial laryngectomy.
    Oral Oncol. 2022;134:106088.
    PubMed     Abstract available


  206. YUAN H, Yan M, Liang X, Liu W, et al
    Decoding the associations between cell functional states in head and neck cancer based on single-cell transcriptome.
    Oral Oncol. 2022;134:106110.
    PubMed     Abstract available


  207. BALACHANDER K, Vijayashree Priyadharsini J, Paramasivam A
    Advances in oral cancer early diagnosis and treatment strategies with liquid biopsy-based approaches.
    Oral Oncol. 2022;134:106108.
    PubMed    


  208. TAKENAKA Y, Takemoto N, Otsuka T, Nishio M, et al
    Predictive significance of body composition indices in patients with head and neck squamous cell carcinoma treated with nivolumab: A multicenter retrospective study.
    Oral Oncol. 2022;132:106018.
    PubMed     Abstract available


  209. CHABRILLAC E, Jackson R, Mattei P, D'Andrea G, et al
    Paratracheal lymph node dissection during total (pharyngo-)laryngectomy: A systematic review and meta-analysis.
    Oral Oncol. 2022;132:106017.
    PubMed     Abstract available


  210. DENG W, Zhao G, Li Z, Yang L, et al
    Recovery pattern analysis of swallowing function in patients undergoing total glossectomy and hemiglossectomy.
    Oral Oncol. 2022;132:105981.
    PubMed     Abstract available


    August 2022
  211. CHANDRALEKHA SELVAKUMAR S, Auxzilia Preethi K, Sekar D
    Non-coding RNAs influencing anti PD-1 immunotherapy in head and neck squamous cell carcinoma (HNSCC).
    Oral Oncol. 2022;134:106092.
    PubMed    


  212. YADALAM PK, Anegundi RV, Ramadoss R, Joseph B, et al
    Felodipine repurposed for targeting TRPV1 receptor to relieve oral cancer pain.
    Oral Oncol. 2022;134:106094.
    PubMed    


  213. SEMPRINI J
    Oral cancer screening prevalence in low-income adults before and after the ACA.
    Oral Oncol. 2022;134:106055.
    PubMed     Abstract available


  214. PAZHANI J, Veeraraghavan VP, Jayaraman S
    Aurora kinase in oral cancer: A potential therapeutic target to improve treatment efficiency.
    Oral Oncol. 2022;134:106093.
    PubMed    


  215. KRUTZ M, Acharya P, Chissoe G, Raj V, et al
    Tobacco cessation after head and neck cancer diagnosis is an independent predictor of treatment response and long-term survival.
    Oral Oncol. 2022;134:106072.
    PubMed     Abstract available


  216. HEMPENIUS MA, Bisheshar SK, Slagter-Menkema L, van der Kamp MF, et al
    Inter-assay reliability of programmed cell death-ligand 1 in head and neck squamous cell carcinoma.
    Oral Oncol. 2022;134:106086.
    PubMed     Abstract available


  217. VAISH R, Mittal N, Mahajan A, Rane SU, et al
    Sentinel node biopsy in node negative early oral cancers: Solution to the conundrum!
    Oral Oncol. 2022;134:106070.
    PubMed     Abstract available


  218. MUTHUPANDIAN S, Muralidharan M, Madhavan Y, Hariharan NM, et al
    Prospective role of salivary MicroRNA for early detection - personalized therapy of head and neck squamous cell carcinoma.
    Oral Oncol. 2022;134:106063.
    PubMed    


  219. PARAMASIVAM A
    Circulating circular RNAs: Novel potential biomarkers and therapeutic targets for oral cancer.
    Oral Oncol. 2022;134:106067.
    PubMed    


  220. EZHILARASAN D, Shree Harini K
    Novel mTOR inhibitors: Promising therapeutic interventions in oral cancer therapy.
    Oral Oncol. 2022;133:106066.
    PubMed    


  221. PRASAD M, Veeraraghavan VP, Jayaraman S
    Tumorigenic potential of GLUT4: A therapeutic target for head and neck squamous cell carcinoma.
    Oral Oncol. 2022;133:106061.
    PubMed    


  222. YU C, Zhou Z
    Relationship between young non-smokers and oral cancer: What can we learn?
    Oral Oncol. 2022;133:106064.
    PubMed    


  223. REKHA K, Venkidasamy B, Govindasamy R, Neralla M, et al
    Isothiocyanates (AITC & BITC) bioactive molecules: Therapeutic potential for oral cancer.
    Oral Oncol. 2022;133:106060.
    PubMed    


  224. BALACHANDER K, Abilasha R, Priyadharsini JV, Balamurugan R, et al
    Targeting mitochondria for apoptosis in oral cancer: Therapeutic potential and obstacles.
    Oral Oncol. 2022;133:106059.
    PubMed    


  225. SARODE GS, Kumari N, Gophane R, Ghone U, et al
    Trends and prospects in oral cancer vaccine.
    Oral Oncol. 2022;133:106051.
    PubMed    


  226. MA SJ, Yu H, Khan M, Yu B, et al
    Defining the optimal threshold and prognostic utility of pre-treatment hemoglobin level as a biomarker for survival outcomes in head and neck cancer patients receiving chemoradiation.
    Oral Oncol. 2022;133:106054.
    PubMed     Abstract available


  227. VERDONCK-DE LEEUW I, Dawson C, Licitra L, Eriksen JG, et al
    European Head and Neck Society recommendations for head and neck cancer survivorship care.
    Oral Oncol. 2022;133:106047.
    PubMed     Abstract available


  228. DONA MG, Rollo F, Pichi B, Moretto S, et al
    Updates on Human Papillomavirus-driven oropharyngeal squamous cell carcinomas in a southern European country.
    Oral Oncol. 2022;131:105947.
    PubMed    


    July 2022
  229. DASSE R, Dupin C, Gorphe P, Temam S, et al
    Proposal for an algorithm to avoid neck dissection during salvage total laryngectomy. A GETTEC multicentric study.
    Oral Oncol. 2022;133:106026.
    PubMed     Abstract available


  230. CHOW JCH, Lee AWM, Wong CHL, Ng WT, et al
    Epstein-Barr virus directed screening for nasopharyngeal carcinoma in individuals with positive family history: A systematic review.
    Oral Oncol. 2022;133:106031.
    PubMed     Abstract available


  231. KRISHNAN M, Venkidasamy B
    PEITC: A prospective natural metabolite in oral cancer treatment.
    Oral Oncol. 2022;133:106044.
    PubMed    


  232. YU C, Zhou Z
    Assessment of oral dysfunction after oral cancer treatment.
    Oral Oncol. 2022;133:106046.
    PubMed    


  233. SARODE GS, Sarode SC, Kumari N, Gophane R, et al
    FAP-targeted imaging in oral cancer: Critical viewpoints.
    Oral Oncol. 2022;133:106024.
    PubMed    


  234. YASASVE M, Manjusha M, Saravanan M
    Polymorphism in pro-inflammatory cytokines and their genetic susceptibility towards oral precancerous lesions and oral cancer.
    Oral Oncol. 2022;133:106027.
    PubMed    


  235. KONO M, Saito S, Egloff AM, Allen CT, et al
    The mouse oral carcinoma (MOC) model: A 10-year retrospective on model development and head and neck cancer investigations.
    Oral Oncol. 2022;132:106012.
    PubMed     Abstract available


  236. MELO G, Silva CAB, Hague A, Parkinson EK, et al
    Anticancer effects of putative and validated BH3-mimetic drugs in head and neck squamous cell carcinomas: An overview of current knowledge.
    Oral Oncol. 2022;132:105979.
    PubMed     Abstract available


  237. KUMARESAN V, Sivaperumal P, Smiline Girija AS
    Bispecific antibodies targeting tumor-associated metalloprotease and recruit NK cells - Multifunctional therapeutic approach against oral cancer.
    Oral Oncol. 2022;132:106013.
    PubMed    


  238. HUANG H, Li L, Cao Q, Jiang H, et al
    Choroid plexus papilloma of auditory nerve: A case report.
    Oral Oncol. 2022;132:106009.
    PubMed    


  239. RENU K, Veeraraghavan VP, Raj A T, Patil S, et al
    The peroxisome proliferator-activated receptor-alpha (PPAR-alpha): A new therapeutic target for oral cancer.
    Oral Oncol. 2022;132:106007.
    PubMed    


  240. ALLEN JL, Hames RA, Mastroianni NM, Greenstein AE, et al
    Evaluation of the matrix metalloproteinase 9 (MMP9) inhibitor Andecaliximab as an Anti-invasive therapeutic in Head and neck squamous cell carcinoma.
    Oral Oncol. 2022;132:106008.
    PubMed     Abstract available


  241. SARODE GS, Kumari N, Sarode SC
    Oral cancer histopathology images and artificial intelligence: A pathologist's perspective.
    Oral Oncol. 2022;132:105999.
    PubMed    


  242. DE VRIES J, Poelman A, Sidorenkov G, Festen S, et al
    The association of frailty and outcomes of geriatric assessment with acute radiation-induced toxicity in patients with head and neck cancer.
    Oral Oncol. 2022;130:105933.
    PubMed     Abstract available


  243. RIBEIRO MFA, Oliveira MCM, Leite AC, Bruzinga FFB, et al
    Assessment of screening programs as a strategy for early detection of oral cancer: a systematic review.
    Oral Oncol. 2022;130:105936.
    PubMed     Abstract available


  244. TANG R, Mao S, Liu S, Li Z, et al
    Types of endoscopic surgical approaches for benign parapharyngeal space tumors.
    Oral Oncol. 2022;130:105875.
    PubMed    


  245. EZHILARASAN D, Shree Harini K, Lakshmi T
    Osteopontin: A reliable diagnostic marker and an attractive therapeutic target in oral cancers.
    Oral Oncol. 2022;132:106005.
    PubMed    


    June 2022
  246. MISRA SR, Das R
    Central oral medicine repository: A proposal to speed up the diagnostic process for oral potentially malignant disorders and oral carcinoma!
    Oral Oncol. 2022;132:105998.
    PubMed    


  247. BALACHANDER K, Paramasivam A
    Anti-PD-1 agent: A promising immunotherapy drug for oral cancer?
    Oral Oncol. 2022;132:105997.
    PubMed    


  248. BABU S, Krishnan M, Priya Veeraraghavan V, Jayaraman S, et al
    Role of salivary miRNAs in the diagnosis and prognosis of head and neck squamous cell carcinoma.
    Oral Oncol. 2022;132:105993.
    PubMed    


  249. ALESSANDRINI L, Ferrari M, Taboni S, Sbaraglia M, et al
    Tumor-stroma ratio, neoangiogenesis and prognosis in laryngeal carcinoma. A pilot study on preoperative biopsies and matched surgical specimens.
    Oral Oncol. 2022;132:105982.
    PubMed     Abstract available


  250. SHREE HARINI K, Ezhilarasan D, Lakshmi T
    Novel fibroblast growth factor receptor inhibitors: Potential therapeutic approach in oral cancer treatment.
    Oral Oncol. 2022;132:105983.
    PubMed    


  251. REVATHI D, Dhanraj G, Ashok V
    Immune check point inhibitors: A promising therapeutic approach in oral cancer.
    Oral Oncol. 2022;132:105977.
    PubMed    


  252. SEKARAN S, Pitchaiah S, Ganapathy D
    Can miR-21 be considered as a potential biomarker and a therapeutic target in oral cancer?
    Oral Oncol. 2022;131:105973.
    PubMed    


  253. ZONG J, Ji P, Lin C, Zhang R, et al
    Plasma Epstein-Barr viral DNA load after completion of two cycles of induction chemotherapy predicts outcomes for patients with advanced-stage nasopharyngeal carcinoma.
    Oral Oncol. 2022;131:105972.
    PubMed     Abstract available


  254. BALACHANDER K, Paramasivam A
    Ferroptosis: An emerging therapeutic target for oral cancer.
    Oral Oncol. 2022;131:105970.
    PubMed    


  255. GANAPATHY D, Sekaran S, Pitchaiah S
    Is prognostic monitoring of high-risk populations at risk for oral cancer necessary after infection with COVID-19?
    Oral Oncol. 2022;131:105968.
    PubMed    


  256. LUO HD, Xia FJ, Wu JH, Yi B, et al
    Efficacy of chemoradiotherapy in survival of stage nasopharyngeal carcinoma and establishment of a prognostic model.
    Oral Oncol. 2022;131:105927.
    PubMed     Abstract available


  257. SHREE HARINI K, Ezhilarasan D, Lakshmi T
    Patient derived tumour organoids: An emerging strategy in oral cancer research and therapeutics.
    Oral Oncol. 2022;131:105954.
    PubMed    


  258. VARGHESE BT, Nair SP, Janardhan D
    Transglottic intralaryngeal papillary thyroid carcinoma.
    Oral Oncol. 2022;131:105935.
    PubMed     Abstract available


  259. YANG Z, Liao J, Schumaker L, Carter-Cooper B, et al
    Simultaneously targeting ErbB family kinases and PI3K in HPV-positive head and neck squamous cell carcinoma.
    Oral Oncol. 2022;131:105939.
    PubMed     Abstract available


  260. SHREE HARINI K, Ezhilarasan D
    Promising autophagy inhibitors: Therapeutic implications in oral cancer.
    Oral Oncol. 2022;131:105948.
    PubMed    


  261. DE FELICE F
    FLASH radiotherapy in head and neck cancer: Myth or reality?
    Oral Oncol. 2022;131:105953.
    PubMed    


  262. FERRELI F, Pirola F, Di Santo D, De Virgilio A, et al
    A critical analysis of the classifications of squamous cell carcinoma of the nasal vestibule.
    Oral Oncol. 2022;129:105880.
    PubMed    


    May 2022
  263. JAYARAMAN S, Pazhani J, PriyaVeeraraghavan V, Raj AT, et al
    PCNA and Ki67: Prognostic proliferation markers for oral cancer.
    Oral Oncol. 2022;130:105943.
    PubMed    


  264. BALACHANDER K, Paramasivam A
    Selective autophagy as a potential therapeutic target for oral cancer.
    Oral Oncol. 2022;130:105934.
    PubMed    


  265. PATIL VM, Kolkur M, Kumar Chinthala S, Waratkar G, et al
    Long term toxicity and tolerance of concurrent docetaxel with radiotherapy in cisplatin-ineligible head and neck cancer patients.
    Oral Oncol. 2022;130:105908.
    PubMed    


  266. UEDA Y, Okano S, Enokida T, Fujisawa T, et al
    Nivolumab for recurrent or metastatic head and neck cancer patients with non-squamous cell carcinoma and/or a primary subsite excluded from CheckMate141, a retrospective study.
    Oral Oncol. 2022;130:105932.
    PubMed     Abstract available


  267. WARNER L, O'Hara JT, Lin DJ, Oozeer N, et al
    Transoral robotic surgery and neck dissection alone for head and neck squamous cell carcinoma: Influence of resection margins on oncological outcomes.
    Oral Oncol. 2022;130:105909.
    PubMed     Abstract available


  268. VARGHESE BT, Shivanesan P
    Anatomical distortion of the right recurrent laryngeal nerve in level 7 neck dissection.
    Oral Oncol. 2022;130:105929.
    PubMed    


  269. SMILINE GIRIJA AS
    Natural "epidrugs" and the need of basket trials in the treatment of oral cancer in India.
    Oral Oncol. 2022;130:105931.
    PubMed    


  270. SHIAO JC, Holt D, Ladbury C, Gao D, et al
    The role of concomitant chemoradiotherapy versus radiation alone in T1-3N0 HPV-positive and HPV-negative oropharyngeal squamous cell carcinoma.
    Oral Oncol. 2022;130:105907.
    PubMed     Abstract available


  271. LOW SK, Reed CT, Millo C, Turkbey EB, et al
    Cecal mass: An unusual site of metastasis from HPV-associated oropharyngeal cancer.
    Oral Oncol. 2022;130:105928.
    PubMed    


  272. PARAMASIVAM A
    Plasma circulating tumor DNA as a molecular marker for oral cancer.
    Oral Oncol. 2022;130:105926.
    PubMed    


  273. SELVARAJ J, Yasothkumar D, Vishnu Priya V, Raj AT, et al
    Development and tumorigenic potential of TP53: A therapeutic target for head and neck squamous cell carcinoma.
    Oral Oncol. 2022;130:105922.
    PubMed    


  274. YANG X, Song H, Ji T, Du G, et al
    The implications of gene mutations in salivary DNA for noninvasive diagnosis of head and neck cancer with a focus on oral cancer.
    Oral Oncol. 2022;130:105924.
    PubMed     Abstract available


  275. FORNER D, Mok F, Verma N, Karam I, et al
    Placement technique impacts gastrostomy tube-related complications amongst head and neck cancer patients.
    Oral Oncol. 2022;130:105903.
    PubMed     Abstract available


  276. PAZHANI J, Jayaraman S, Veeraraghavan VP, Somasundaram DB, et al
    Targeting cancer associated fibroblasts - A TGF-beta based immunotherapy for head and neck squamous cell carcinoma.
    Oral Oncol. 2022;130:105899.
    PubMed    


  277. JIANG Y, Yang S, Qi Y
    Comment on: The prognostic value of radiologic extranodal extension in nasopharyngeal carcinoma: Systematic review and meta-analysis.
    Oral Oncol. 2022;130:105872.
    PubMed    


  278. MADY LJ, Baddour K, Hodges JC, Magana LC, et al
    Corrigendum to "The impact of frailty on mortality in non-surgical head and neck cancer treatment: Shifting the clinical paradigm" [Oral Oncol. 126 (2022) 105766].
    Oral Oncol. 2022 May 2:105882. doi: 10.1016/j.oraloncology.2022.105882.
    PubMed    


  279. SWARTZ JE, Smits HJG, Philippens MEP, de Bree R, et al
    Correlation and colocalization of HIF-1alpha and pimonidazole staining for hypoxia in laryngeal squamous cell carcinomas: A digital, single-cell-based analysis.
    Oral Oncol. 2022;128:105862.
    PubMed     Abstract available


  280. YEOM S, Jung EK, Lee DH, Lee JK, et al
    Clinical features and recurrence factors of benign neoplasms of the tongue base.
    Oral Oncol. 2022;128:105866.
    PubMed     Abstract available


  281. MULLER RG, Hamill CS, Vu B, Thuener J, et al
    Impact of AJCC 8th edition staging system and definitive treatment choice on the prognosis of complete responders with p16+ and p16- oropharyngeal squamous cell carcinomas.
    Oral Oncol. 2022;128:105861.
    PubMed     Abstract available


    April 2022
  282. GALLOGLY JA JR, Weber AK, Mazul AL, Brinkmeier JV, et al
    Inferior outcomes associated with emergency department presentation for head and neck cancer surgery.
    Oral Oncol. 2022;129:105894.
    PubMed     Abstract available


  283. SHE L, Tian K, Han J, Zuo W, et al
    Pembrolizumab with or without chemotherapy versus cetuximab plus chemotherapy to treat recurrent or metastatic head and neck squamous cell carcinoma: An updated KEYNOTE-048 based cost-effectiveness analysis.
    Oral Oncol. 2022;129:105871.
    PubMed     Abstract available


  284. KATO A, Matsuda Y, Morioka R, Okui T, et al
    Discrepancy between subjective and objective postoperative oral dysfunction assessment after oral cancer treatment: A single-center cross-sectional study.
    Oral Oncol. 2022;129:105879.
    PubMed     Abstract available


  285. HAIST C, Poschinski Z, Bister A, Hoffmann MJ, et al
    Engineering a single-chain variable fragment of cetuximab for CAR T-cell therapy against head and neck squamous cell carcinomas.
    Oral Oncol. 2022;129:105867.
    PubMed     Abstract available


  286. SEKAR D, Panagal M, Manimaran D, Ahmad N, et al
    miR-185 and its anti-miR as a biomarker and therapeutic target for oral cancer.
    Oral Oncol. 2022;129:105873.
    PubMed    


  287. LIU T, Ma L, Song L, Yan B, et al
    CENPM upregulation by E5 oncoprotein of human papillomavirus promotes radiosensitivity in head and neck squamous cell carcinoma.
    Oral Oncol. 2022;129:105858.
    PubMed     Abstract available


  288. NERALLA M, Senthilnthan P, Kubendiran D, Nandan A, et al
    Dry needle therapy for post operative shoulder dysfunction in oral cancer patients.
    Oral Oncol. 2022;128:105865.
    PubMed    


  289. PETRELLI F, Trevisan F, Ghidini A, Capriotti V, et al
    Comparison of platinum-based regimens in combination with radiotherapy for head and neck cancers: A network meta-analysis.
    Oral Oncol. 2022;128:105864.
    PubMed    


  290. ZHOU S, Chan C, Rulach R, Dyab H, et al
    Long term survival in patients with human papillomavirus-positive oropharyngeal cancer and equivocal response on 12-week PET-CT is not compromised by the omission of neck dissection.
    Oral Oncol. 2022;128:105870.
    PubMed     Abstract available


  291. YANG ZC, Nie ZQ, Chen QY, Du CC, et al
    Cost-Effectiveness analysis of combining plasma Epstein-Barr virus DNA testing and different surveillance imaging modalities for nasopharyngeal carcinoma patients in first remission.
    Oral Oncol. 2022;128:105851.
    PubMed     Abstract available


  292. FENG G, Feng H, Qi Y, Wang T, et al
    Interaction analysis between germline genetic variants and somatic mutations in head and neck cancer.
    Oral Oncol. 2022;128:105859.
    PubMed     Abstract available


  293. CHEN Y, Zheng X, Lin J, Gao X, et al
    A high homologous recombination deficiency score is associated with poor survival and a non-inflamed tumor microenvironment in head and neck squamous cell carcinoma patients.
    Oral Oncol. 2022;128:105860.
    PubMed     Abstract available


  294. TIAN K, Han J, Wang Z, Chen J, et al
    Immune checkpoint inhibition in first-line treatment for recurrent or metastatic nasopharyngeal carcinoma: A CAPTAIN-1st and JUPITER-02 trial-based cost-effectiveness analysis.
    Oral Oncol. 2022;128:105842.
    PubMed     Abstract available


  295. BALACHANDER K, Roy A, Priyadharsini JV, Murugan S, et al
    Mitochondrial DNA in circulating exosomes: A novel biomarker and potential therapeutic target for oral cancer.
    Oral Oncol. 2022;128:105857.
    PubMed    


  296. DE LA COUR CD, Munk C, Aalborg GL, Kjaer SK, et al
    Base of tongue/tonsillar and laryngeal cancer in Denmark 1994-2018: Temporal trends in incidence according to education and age.
    Oral Oncol. 2022;128:105832.
    PubMed     Abstract available


  297. BANERJEE A, Misra SR, Roy B, Singh S, et al
    Central oral histopathology registry (COHR) - A proposal promising hope for oral cancer and oral pathology research.
    Oral Oncol. 2022;128:105856.
    PubMed    


  298. SEKAR D, Murthykumar K, Ganapathy D
    miR-206 and its mimics: A predictive biomarker and therapeutic molecule in the treatment of oral cancer.
    Oral Oncol. 2022;128:105849.
    PubMed    


  299. RISCHIN D, Harrington KJ, Greil R, Soulieres D, et al
    Pembrolizumab alone or with chemotherapy for recurrent or metastatic head and neck squamous cell carcinoma: Health-related quality-of-life results from KEYNOTE-048.
    Oral Oncol. 2022;128:105815.
    PubMed     Abstract available


  300. TANS L, Al-Mamgani A, Kwa SLS, Elbers JBW, et al
    Single vocal cord irradiation for early-stage glottic cancer: Excellent local control and favorable toxicity profile.
    Oral Oncol. 2022;127:105782.
    PubMed     Abstract available


  301. DODDAWAD VG, Premalatha BR, Sreeshyla HS, Nitin P, et al
    Classification staging systems on clinical and radiographic features of inverted sinonasal papilloma: A case report.
    Oral Oncol. 2022;127:105768.
    PubMed     Abstract available


    March 2022
  302. PATIL V, Noronha V, Joshi A, Menon N, et al
    RMAC study: A randomized study for evaluation of metronomic adjuvant chemotherapy in recurrent head and neck cancers post salvage surgical resection in those who are ineligible for re-irradiation.
    Oral Oncol. 2022;128:105816.
    PubMed     Abstract available


  303. CHANG CT, Liu SP, Muo CH, Liao YF, et al
    The impact of dental therapy timelines and irradiation dosages on osteoradionecrosis in oral cancer patients: A population-based cohort study.
    Oral Oncol. 2022;128:105827.
    PubMed     Abstract available


  304. HSIEH MC, Wang CC, Yang CC, Lien CF, et al
    The role of induction chemotherapy in patients with locally advanced head and neck squamous cell carcinoma: A nationwide population-based matched study.
    Oral Oncol. 2022;128:105848.
    PubMed     Abstract available


  305. YANG X, Xu X, Zhang C, Ji T, et al
    The diagnostic value and prospects of gene mutations in circulating tumor DNA for head and neck cancer monitoring.
    Oral Oncol. 2022;128:105846.
    PubMed     Abstract available


  306. RANJAN MISRA S, Das R
    Tele-screening for early detection of oral cancer during the COVID-19 pandemic era: Diagnostic pitfalls and potential misinterpretations!
    Oral Oncol. 2022;128:105845.
    PubMed    


  307. MATTOX AK, D'Souza G, Khan Z, Allen H, et al
    Comparison of next generation sequencing, droplet digital PCR, and quantitative real-time PCR for the earlier detection and quantification of HPV in HPV-positive oropharyngeal cancer.
    Oral Oncol. 2022;128:105805.
    PubMed     Abstract available


  308. BALACHANDER K, Paramasivam A
    Cell-free mitochondrial DNA as a novel non-invasive biomarker for oral cancer.
    Oral Oncol. 2022;127:105825.
    PubMed    


  309. YAMAGUMA Y, Kaneuji T, Shirouzu S, Fukui T, et al
    Combination therapy of Mohs paste and chemotherapy improved metastatic oral cancer to the precordium skin and bilateral axillary lymph nodes: A case report.
    Oral Oncol. 2022;127:105817.
    PubMed     Abstract available


  310. VILLARD A, Breuskin I, Casiraghi O, Asmandar S, et al
    Confocal laser endomicroscopy and confocal microscopy for head and neck cancer imaging: Recent updates and future perspectives.
    Oral Oncol. 2022;127:105826.
    PubMed     Abstract available


  311. PATIL V, Alone M, Rai R, Noronha V, et al
    Safety and efficacy of pembrolizumab with chemotherapy in locally advanced head and neck cancers.
    Oral Oncol. 2022;127:105824.
    PubMed    


  312. DE LUCA P, Di Stadio A, Tassone D, de Campora L, et al
    Large cervical mass and head and neck cancer. First report of ectopic papillary adenoma of the lung.
    Oral Oncol. 2022;127:105823.
    PubMed     Abstract available


  313. DEVARAJA K, Kabekkodu SP
    Oral microbiome; a potential game-changer in the management of oral cancer?
    Oral Oncol. 2022;127:105822.
    PubMed    


  314. BONETTI VALENTE V, Mantovan Mazzon B, Urbano Collado F, Conrado Neto S, et al
    Clinicopathological and prognostic profile of non-smoking and non-drinking head and neck cancer patients: a population-based comparative study.
    Oral Oncol. 2022;127:105799.
    PubMed     Abstract available


  315. SHETH S, Gilbert J, Deal AM, Chera B, et al
    Mature follow up of induction chemotherapy with carboplatin, nab-paclitaxel, cetuximab in head and neck squamous cell carcinoma.
    Oral Oncol. 2022;127:105807.
    PubMed    


  316. VALERO C, Yuan A, Zanoni DK, Lei E, et al
    Young non-smokers with oral cancer: What are we missing and why?
    Oral Oncol. 2022;127:105803.
    PubMed     Abstract available


  317. ELUMALAI P, Ezhilarasan D, Lakshmi T
    Targeting head and neck cancer epigenetics with CRISPR-dCas9: An emerging therapeutic approach.
    Oral Oncol. 2022;127:105801.
    PubMed    


  318. GLAZAR DJ, Johnson M, Farinhas J, Steuer CE, et al
    Early response dynamics predict treatment failure in patients with recurrent and/or metastatic head and neck squamous cell carcinoma treated with cetuximab and nivolumab.
    Oral Oncol. 2022;127:105787.
    PubMed     Abstract available


  319. ROUTILA J, Qiao X, Weltner J, Rantala JK, et al
    Cisplatin overcomes radiotherapy resistance in OCT4-expressing head and neck squamous cell carcinoma.
    Oral Oncol. 2022;127:105772.
    PubMed     Abstract available


  320. BRODY RM, Shimunov D, Cohen RB, Lin A, et al
    A benchmark for oncologic outcomes and model for lethal recurrence risk after transoral robotic resection of HPV-related oropharyngeal cancers.
    Oral Oncol. 2022;127:105798.
    PubMed     Abstract available


  321. GONCALVES JM, Scarini JF, Gondak R, Altemani A, et al
    Oral involvement of sinonasal undifferentiated carcinoma: A case report and immunohistochemical study of a challenging case.
    Oral Oncol. 2022;126:105779.
    PubMed     Abstract available


  322. SAKTHIVEL P, Raveendran S, Rajeshwari M
    Sinonasal small round blue cell tumors: What the clinician must know!
    Oral Oncol. 2022;126:105735.
    PubMed    


  323. PETRIDES GA, Dunn M, Charters E, Venchiarutti R, et al
    Health-related quality of life in maxillectomy patients undergoing dentoalveolar rehabilitation.
    Oral Oncol. 2022;126:105757.
    PubMed     Abstract available


    February 2022
  324. QURESHI HA, Zhu X, Yang GH, Steadele M, et al
    Impact of HPV status on immune responses in head and neck squamous cell carcinoma.
    Oral Oncol. 2022;127:105774.
    PubMed     Abstract available


  325. BELGIOIA L, Becherini C, Bacigalupo A, Bonomo P, et al
    Chemo- immunotherapy and radiation in locally advanced head and neck cancer: Where do we stand?
    Oral Oncol. 2022;127:105773.
    PubMed     Abstract available


  326. DAGLINAMRATA, Lakshmi T, Rushabh D, Dineshkumar T, et al
    Telescreening as an alternate modality for early detection of oral cancer.
    Oral Oncol. 2022;127:105785.
    PubMed    


  327. HARING CT, Dermody SM, Yalamanchi P, Kang SY, et al
    The future of circulating tumor DNA as a biomarker in HPV related oropharyngeal squamous cell carcinoma.
    Oral Oncol. 2022;126:105776.
    PubMed     Abstract available


  328. MICHMERHUIZEN NL, Heenan C, Wang J, Leonard E, et al
    Combined Pik3ca-H1047R and loss-of-function Notch1 alleles decrease survival time in a 4-nitroquinoline N-oxide-driven head and neck squamous cell carcinoma model.
    Oral Oncol. 2022;126:105770.
    PubMed    


  329. MADY LJ, Baddour K, Hodges JC, Magana LC, et al
    The impact of frailty on mortality in non-surgical head and neck cancer treatment: Shifting the clinical paradigm.
    Oral Oncol. 2022;126:105766.
    PubMed     Abstract available


  330. ZHANG S, Zhang W, Zhang J
    Comprehensive analysis of immune cell infiltration and significant genes in head and neck squamous cell carcinoma.
    Oral Oncol. 2022;126:105755.
    PubMed     Abstract available


  331. LI JL, Hsieh TL, Ou MC, Lin FC, et al
    Prognostic value of neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio during immune checkpoint inhibitor treatment in recurrent or metastatic head and neck squamous cell carcinoma patients.
    Oral Oncol. 2022;126:105729.
    PubMed    


  332. LENOCI D, Carenzo A, Cavalieri S, Pistore F, et al
    Biological properties of hypoxia-related gene expression models/signatures on clinical benefit of anti-EGFR treatment in two head and neck cancer window-of-opportunity trials.
    Oral Oncol. 2022;126:105756.
    PubMed    


  333. CHAN SK, Lin C, Huang SH, Chau TC, et al
    Refining TNM-8 M1 categories with anatomic subgroups for previously untreated de novo metastatic nasopharyngeal carcinoma.
    Oral Oncol. 2022;126:105736.
    PubMed     Abstract available


  334. SILVERMAN DA, Parikh AS, Liu K, Zhan KY, et al
    Predictors of survival following carotid blowout syndrome.
    Oral Oncol. 2022;125:105723.
    PubMed     Abstract available


  335. CHIN O, Alshafai L, O'Sullivan B, Su J, et al
    Inter-rater concordance and operating definitions of radiologic nodal feature assessment in human papillomavirus-positive oropharyngeal carcinoma.
    Oral Oncol. 2022;125:105716.
    PubMed     Abstract available


  336. CHEN TC, Wang C, Su LY, Lin MC, et al
    Impact of invasion into cervical esophagus for patients with hypopharyngeal squamous cell carcinoma.
    Oral Oncol. 2022;125:105683.
    PubMed     Abstract available


    January 2022
  337. SENGUPTA N, Sarode SC, Sarode GS, Ghone U, et al
    Scarcity of publicly available oral cancer image datasets for machine learning research.
    Oral Oncol. 2022;126:105737.
    PubMed     Abstract available


  338. JONAS H, Simnica D, Bussmann L, Zech H, et al
    Early relapse detection by monitoring of circulating cell-free DNA in patients with localized head and neck squamous cell carcinoma: A subgroup analysis of the multicenter randomized clinical trial IMSTAR-HN.
    Oral Oncol. 2022;126:105733.
    PubMed    


  339. SEKAR D
    Inhibition of OSCC derived ExomiRs and its therapeutic applications in oral cancer.
    Oral Oncol. 2022;126:105747.
    PubMed    


  340. FERRAZZO KL
    Regarding: "Clinical practice guidelines for dental management prior to radiation for head and neck cancer".
    Oral Oncol. 2022;126:105731.
    PubMed    


  341. WARD MC, Miller JA, Walker GV, Moeller BJ, et al
    The economic impact of circulating tumor-tissue modified HPV DNA for the post-treatment surveillance of HPV-driven oropharyngeal cancer: A simulation.
    Oral Oncol. 2022;126:105721.
    PubMed     Abstract available


  342. LIU X, Li WF, Ding C, Chen L, et al
    Differential benefit of induction chemotherapy according to body mass index in nasopharyngeal carcinoma - Pooled analysis of two randomized trials.
    Oral Oncol. 2022;125:105718.
    PubMed     Abstract available


  343. K AP, Selvakumar SC, Selvaraj J, Mony U, et al
    Reviewing the potential application of miR-21 inhibitors in oral cancer therapeutics.
    Oral Oncol. 2022;125:105713.
    PubMed    


  344. ECONOMOPOULOU P, Kotsantis I, Psyrri A
    Radiotherapy and immunotherapy combination in head and neck cancer: Does current failure qualify as an ending or is it a key to future success?
    Oral Oncol. 2022 Jan 13:105717. doi: 10.1016/j.oraloncology.2022.105717.
    PubMed    


  345. CARDIN GB, Bernard M, Bourbonnais J, Bahig H, et al
    The rs6942067 genotype is associated with a worse overall survival in young or non-smoking HPV-negative patients with positive nodal status in head and neck squamous cell carcinoma.
    Oral Oncol. 2022;125:105696.
    PubMed    


  346. GILLIGAN G, Piemonte E, Lazos J, Panico R, et al
    Chronic wounds of traumatic origin and oral cancer arising de novo: A potential association?
    Oral Oncol. 2022;125:105711.
    PubMed    


  347. PATIL V, Ghandade N, Noronha V, Menon N, et al
    Hypomagnesemia in patients with locally advanced head and neck cancer treated weekly cisplatin-incidence and impact on outcomes.
    Oral Oncol. 2022;125:105709.
    PubMed    


  348. VIITASALO S, Karhemo PR, Vaananen J, Ilmarinen T, et al
    Exome sequencing reveals candidate mutations implicated in sinonasal carcinoma and malignant transformation of sinonasal inverted papilloma.
    Oral Oncol. 2022;124:105663.
    PubMed     Abstract available


  349. SAKTHIVEL P, Thakar A, Fernandez-Fernandez MM, Panda S, et al
    TransOral UltraSonic surgery (TOUSS) for oral cavity, oropharyngeal and supraglottic malignancy: A prospective study of feasibility, safety, margins, functional and survival outcomes.
    Oral Oncol. 2022;124:105643.
    PubMed     Abstract available


  350. LI MM, Mroz EA, Faquin WC, Lott-Limbach A, et al
    ERalpha: A biomarker and treatment target for oropharyngeal cancer?
    Oral Oncol. 2022;124:105637.
    PubMed    


  351. MALIK A, Panda S, Sakthivel P
    Treatment of early glottic carcinoma: Is it a paradox of choices?
    Oral Oncol. 2022;124:105516.
    PubMed    


  352. ZHANG L, Chen L, Xiao M, Xie X, et al
    Locally advanced undifferentiated sarcomatoid carcinoma of the right maxillary sinus with PDCD6-TERT fusion: A rare case report.
    Oral Oncol. 2022;124:105466.
    PubMed     Abstract available


    December 2021
  353. COHEN O, Brauer PR, Judson BL, Burtness BA, et al
    Guideline - Adherence in advanced stage head and neck cancer is associated with improved survival - A National study.
    Oral Oncol. 2021;125:105694.
    PubMed     Abstract available


  354. WANG J, Tian Y, Huang H, Huang D, et al
    The prognosis of HPV-associated metastatic pharyngeal patients by primary and distant site.
    Oral Oncol. 2021;125:105675.
    PubMed     Abstract available


  355. SUBASH A, Bylapudi B, Thakur S, Rao VUS, et al
    Oral cancer in India, a growing problem: Is limiting the exposure to avoidable risk factors the only way to reduce the disease burden?
    Oral Oncol. 2021;125:105677.
    PubMed     Abstract available


  356. MERCHANT YP, Mohan M, Shetty S, Bandemegal M, et al
    The submandibular gland in neck dissection: A necessary casualty or a hapless victim?
    Oral Oncol. 2021;125:105678.
    PubMed    


  357. HERNDON P, Jassal JS, Cramer JD
    Association between E-cigarette use and oral HPV-16 infection.
    Oral Oncol. 2021;125:105676.
    PubMed    


  358. DOU Y, Ma C, Wang K, Liu S, et al
    Dysbiotic tumor microbiota associates with head and neck squamous cell carcinoma outcomes.
    Oral Oncol. 2021;124:105657.
    PubMed     Abstract available


  359. NOJI R, Kano Y, Hirai H, Onishi I, et al
    MYC-PDL1 axis reduces sensitivity to nivolumab in recurrent head and neck squamous cell carcinoma.
    Oral Oncol. 2021;124:105666.
    PubMed     Abstract available


  360. WEI LY, Lin HC, Tsai FC, Ko JY, et al
    Effects of Interleukin-6 on STAT3-regulated signaling in oral cancer and as a prognosticator of patient survival.
    Oral Oncol. 2021;124:105665.
    PubMed     Abstract available


  361. SARI SY, Yilmaz MT, Aktas BY, Aksoy S, et al
    Results of concurrent radiotherapy and immunotherapy in recurrent and metastatic head and neck cancer: A single-center experience.
    Oral Oncol. 2021;124:105658.
    PubMed     Abstract available


  362. CRAMER JD, Grauer J
    Modeling oral cancer screening in the United States population.
    Oral Oncol. 2021;124:105656.
    PubMed     Abstract available


  363. BIGELOW EO, Windon MJ, Fakhry C, Kiess AP, et al
    Development of a web-based, patient-centered decision aid for oropharyngeal cancer treatment.
    Oral Oncol. 2021;123:105618.
    PubMed     Abstract available


  364. BURNINGHAM K, Moore W, Moon D, Avkshtol V, et al
    Prognostic impact of matted lymphadenopathy in patients with oropharyngeal squamous cell carcinoma treated with definitive chemoradiotherapy.
    Oral Oncol. 2021;123:105623.
    PubMed     Abstract available


    November 2021
  365. GUPTA T, Maheshwari G, Kannan S, Nair S, et al
    Systematic review and meta-analysis of randomized controlled trials comparing elective neck dissection versus sentinel lymph node biopsy in early-stage clinically node-negative oral and/or oropharyngeal squamous cell carcinoma: Evidence-base for pract
    Oral Oncol. 2021;124:105642.
    PubMed     Abstract available


  366. CHAUHAN A, Kaur R, Ghoshal S, Chatterjee D, et al
    Potential prognostic and predictive role of baseline circulating tumor cells in head and neck squamous cell carcinoma.
    Oral Oncol. 2021;124:105636.
    PubMed    


  367. FUEREDER T, Minichsdorfer C, Mittlboeck M, Wagner C, et al
    Pembrolizumab plus docetaxel for the treatment of recurrent/metastatic head and neck cancer: A prospective phase I/II study.
    Oral Oncol. 2021;124:105634.
    PubMed     Abstract available


  368. DENARO N, Merlano M, Garrone O
    In reply to immune desert in head and neck squamous cell carcinoma: A review of challenges and opportunities for modulating the tumor immune microenvironment.
    Oral Oncol. 2021;124:105640.
    PubMed    


  369. THADURI A, Dungala D, Panuganti A, Majumdar KS, et al
    Addressing the challenges of head and neck cancer care in India - A compelling need of the hour.
    Oral Oncol. 2021;124:105638.
    PubMed    


  370. MADHULAXMI M, Abhinav RP
    Protein changes of WNT signaling pathway in oral cancer.
    Oral Oncol. 2021;123:105624.
    PubMed    


  371. KOWALCHUK RO, Van Abel KM, Yin LX, Garcia J, et al
    Correlation between radiographic and pathologic lymph node involvement and extranodal extension via CT and PET in HPV-associated oropharyngeal cancer.
    Oral Oncol. 2021;123:105625.
    PubMed     Abstract available


  372. GAU M, Fonseca A, Ozsahin M, Fayette J, et al
    Prognostic impact of extranodal extension in resected head and neck squamous cell carcinomas in the era of postoperative chemoradiation: A retrospective monocentric study.
    Oral Oncol. 2021;123:105605.
    PubMed     Abstract available


  373. MISHRA S, Subash A, Rao VUS, Thakur S, et al
    Role of neoadjuvant chemotherapy in head and neck cancer management: A case for exploring diverse treatment strategies for evaluating long-term efficacy.
    Oral Oncol. 2021;123:105594.
    PubMed    


  374. GOLUSINSKI P, Corry J, Poorten VV, Simo R, et al
    De-escalation studies in HPV-positive oropharyngeal cancer: How should we proceed?
    Oral Oncol. 2021;123:105620.
    PubMed     Abstract available


  375. WATSON E, Dorna Mojdami Z, Oladega A, Hope A, et al
    Clinical practice guidelines for dental management prior to radiation for head and neck cancer.
    Oral Oncol. 2021;123:105604.
    PubMed     Abstract available


  376. BRIL SI, Chargi N, Wendrich AW, Wegner I, et al
    Validation of skeletal muscle mass assessment at the level of the third cervical vertebra in patients with head and neck cancer.
    Oral Oncol. 2021;123:105617.
    PubMed     Abstract available


  377. WANG Y, Gao Y, Yuan L, Zhang J, et al
    Psychological needs and associated factors among perioperative patients with oral cancer.
    Oral Oncol. 2021;123:105615.
    PubMed    


  378. GRONLUND MP, Jakobsen KK, Mirian C, Gronhoj C, et al
    Nasopharyngeal malignancies in Denmark diagnosed from 1980 to 2014.
    Oral Oncol. 2021;122:105583.
    PubMed     Abstract available


  379. YU J, Tsay C, Sasaki C, Son YH, et al
    Brachytherapy and non-cancer mortality in patients with oral cavity and oropharynx SCCs.
    Oral Oncol. 2021;122:105585.
    PubMed     Abstract available


  380. SEE A, Chu C, Kiong KL, Teo C, et al
    Surgical salvage of recurrent nasopharyngeal cancer- a multi-institutional review.
    Oral Oncol. 2021;122:105556.
    PubMed    


  381. SAKTHIVEL P, Ramanikanth TV, Thakar A, Singh CA, et al
    TransOral UltraSonic Surgery (TOUSS) assisted supraglottic laryngectomy: Expanding the spectrum of endoscopic head and neck surgeries.
    Oral Oncol. 2021;122:105562.
    PubMed    


  382. THAKAR A, Sakthivel P, Sikka K
    TransOral UltraSonic Surgery (TOUSS) and TransOral Laser (TOL) assisted supraglottic laryngectomy (TOUSS-TOL-SGL): Improvising techniques within the transoral corridor.
    Oral Oncol. 2021;122:105573.
    PubMed    


  383. LIN N, Gao J, Wang H, Zhang H, et al
    Diagnostic value of indocyanine green for sentinel lymph node mapping and lymph node metastasis in oral/oropharyngeal carcinoma.
    Oral Oncol. 2021;122:105563.
    PubMed     Abstract available


  384. RE M, Tomasetti M, Monaco F, Amati M, et al
    NGS-based miRNome identifies miR-449 cluster as marker of malignant transformation of sinonasal inverted papilloma.
    Oral Oncol. 2021;122:105554.
    PubMed     Abstract available


  385. MCDOWELL L, Casswell G, Bressel M, Drosdowsky A, et al
    Symptom burden, quality of life, functioning and emotional distress in survivors of human papillomavirus associated oropharyngeal cancer: An Australian cohort.
    Oral Oncol. 2021;122:105560.
    PubMed     Abstract available


  386. MIN PARK Y, Yol Lim J, Woo Koh Y, Kim SH, et al
    Prediction of treatment outcome using MRI radiomics and machine learning in oropharyngeal cancer patients after surgical treatment.
    Oral Oncol. 2021;122:105559.
    PubMed     Abstract available


    October 2021
  387. GEORGE A, Saseendran A, Joseph ST, Gopal KR, et al
    Submandibular gland - The victim of neck dissection.
    Oral Oncol. 2021;123:105591.
    PubMed    


  388. CABEZAS-CAMARERO S, Alonso-Ovies A, Merino-Menendez S, Cabrera-Martin MN, et al
    Major pathological response and durable locoregional control after neoadjuvant pembrolizumab-carboplatin-paclitaxel in head and neck cancer.
    Oral Oncol. 2021;123:105589.
    PubMed     Abstract available


  389. BRUIJNEN CP, de Groot LGR, Vondeling AM, de Bree R, et al
    Functional decline after surgery in older patients with head and neck cancer.
    Oral Oncol. 2021;123:105584.
    PubMed     Abstract available


  390. PUTHIYOTTIL IV, Subash A, Thakur S, Rao VUS, et al
    Elective neck dissection versus sentinel node biopsy in early oral cavity cancer - Are we ready for transition?
    Oral Oncol. 2021;123:105597.
    PubMed    


  391. SHINN JR, Carey RM, Mady LJ, Shimunov D, et al
    Sex-based differences in outcomes among surgically treated patients with HPV-related oropharyngeal squamous cell carcinoma.
    Oral Oncol. 2021;123:105570.
    PubMed     Abstract available


  392. JOSE MARTELLI A, Assis Machado R, Medeiros Pereira W, Balduino Guimaraes Santos F, et al
    Revaluation of the treatment of head and neck cancer in Brazil during the COVID-19 pandemic - phase 2.
    Oral Oncol. 2021;123:105600.
    PubMed    


  393. YUWANATI M, Sarode SC, Gadbail A, Gondivkar S, et al
    Alcohol attributed Oral Cancer and Oral microbiome: Emerging yet neglected research domain.
    Oral Oncol. 2021;123:105596.
    PubMed    


  394. YU ST, Ge JN, Sun BH, Wei ZG, et al
    Lymph node yield in the initial central neck dissection (CND) associated with the risk of recurrence in papillary thyroid cancer: A reoperative CND cohort study.
    Oral Oncol. 2021;123:105567.
    PubMed     Abstract available


  395. SHU L, Wang D, Nannapaneni S, Sun Y, et al
    Tipifarnib enhances anti-EGFR activity of cetuximab in non-HRas mutated head and neck squamous cell carcinoma cancer (HNSCC).
    Oral Oncol. 2021;122:105546.
    PubMed     Abstract available


  396. MA D, Orner D, Ghaly MM, Parashar B, et al
    Automated health chats for symptom management of head and neck cancer patients undergoing radiation therapy.
    Oral Oncol. 2021;122:105551.
    PubMed     Abstract available


  397. ZHAO Y, Li WF, Li QJ, He SW, et al
    WIPI-1 inhibits metastasis and tumour growth via the WIPI-1-TRIM21 axis and MYC regulation in nasopharyngeal carcinoma.
    Oral Oncol. 2021;122:105576.
    PubMed     Abstract available


  398. ROSENBERG AJ, Agrawal N, Pearson A, Gooi Z, et al
    Risk and response adapted de-intensified treatment for HPV-associated oropharyngeal cancer: Optima paradigm expanded experience.
    Oral Oncol. 2021;122:105566.
    PubMed     Abstract available


  399. TSENG WH, Li TH, Chiu HL, Yang TL, et al
    Long-term swallowing-related outcomes in oral cancer patients receiving proactive swallowing therapy.
    Oral Oncol. 2021;122:105569.
    PubMed     Abstract available


  400. BRIL SI, van Beers MA, Chargi N, Carrillo Minulina N, et al
    Skeletal muscle mass at C3 is a strong predictor for skeletal muscle mass at L3 in sarcopenic and non-sarcopenic patients with head and neck cancer.
    Oral Oncol. 2021;122:105558.
    PubMed    


  401. PENG H, Chen L, Mao YP, Tian L, et al
    Nomogram-aided individual induction chemotherapy regimen selection in advanced nasopharyngeal carcinoma.
    Oral Oncol. 2021;122:105555.
    PubMed     Abstract available


  402. CARNEVALE C, Pagan-Pomar A, Bianchi A, Sarria-Echegaray P, et al
    Right colonic interposition for severe pharyngoesophageal stricture in head and neck patients: A feasible rescue strategy after multiple failed reconstructive options.
    Oral Oncol. 2021;121:105481.
    PubMed     Abstract available


  403. HANS S, Chebib E, Chekkoury-Idrissi Y, Distinguin L, et al
    Surgical and oncological outcomes of transoral robotic total laryngectomy: A case series.
    Oral Oncol. 2021;121:105511.
    PubMed     Abstract available


  404. FINEGERSH A, Voora RS, Panuganti B, Faraji F, et al
    Robotic surgery may improve overall survival for T1 and T2 tumors of the hypopharynx: An NCDB cohort study.
    Oral Oncol. 2021;121:105440.
    PubMed     Abstract available


  405. AL MASALMEH N, Kukreja G, Zaiem F, Raza SN, et al
    p16 positive oropharyngeal small cell cancer: A case report.
    Oral Oncol. 2021;121:105391.
    PubMed     Abstract available


  406. HARING CT, Brummel C, Bhambhani C, Jewell B, et al
    Implementation of human papillomavirus circulating tumor DNA to identify recurrence during treatment de-escalation.
    Oral Oncol. 2021;121:105332.
    PubMed    


    September 2021
  407. CURY SS, Miranda PM, Marchi FA, Canto LMD, et al
    Germline variants in DNA repair genes are associated with young-onset head and neck cancer.
    Oral Oncol. 2021;122:105545.
    PubMed     Abstract available


  408. WANG BC
    Adjuvant chemotherapy in locoregionally advanced nasopharyngeal carcinoma: Finding the suitable population.
    Oral Oncol. 2021 Sep 28:105544. doi: 10.1016/j.oraloncology.2021.105544.
    PubMed    


  409. SARODE SC, Sarode GS, Sengupta N, Ghone U, et al
    Tobacco induced epithelial dysplasia at minor salivary gland excretory duct and oral cancer.
    Oral Oncol. 2021;122:105525.
    PubMed    


  410. MILLIET F, Bozec A, Schiappa R, Viotti J, et al
    Metachronous second primary neoplasia in oropharyngeal cancer patients: Impact of tumor HPV status. A GETTEC multicentric study.
    Oral Oncol. 2021;122:105503.
    PubMed     Abstract available


    August 2021
  411. WRIGHT CM, Lee DY, Shimunov D, Carmona R, et al
    Definitive tumor directed therapy confers a survival advantage for metachronous oligometastatic HPV-associated oropharyngeal cancer following trans-oral robotic surgery.
    Oral Oncol. 2021;121:105509.
    PubMed     Abstract available


  412. MCDOWELL L, Corry J
    Regarding "Comparing unilateral vs. bilateral neck management in lateralized oropharyngeal cancer between surgical and radiation oncologists: An international practice pattern survey" - Intra- and inter-specialty variability and the underutilisation o
    Oral Oncol. 2021;119:105248.
    PubMed    


  413. CHOI N, Kim Z, Song BH, Park W, et al
    Prediction of risk factors for pharyngo-cutaneous fistula after total laryngectomy using artificial intelligence.
    Oral Oncol. 2021;119:105357.
    PubMed     Abstract available


    July 2021
  414. NAUTA IH, Klausch T, van de Ven PM, Hoebers FJP, et al
    The important role of cisplatin in the treatment of HPV-positive oropharyngeal cancer assessed by real-world data analysis.
    Oral Oncol. 2021;121:105454.
    PubMed     Abstract available


  415. KIM C, Martinez E, Kulich M, Swanson MS, et al
    Surgeon practice patterns in transoral robotic surgery for HPV-related oropharyngeal cancer.
    Oral Oncol. 2021;121:105460.
    PubMed     Abstract available


  416. DA COSTA REAR, da Silva Junior RG, Magalhaes LAN, Mendes JR, et al
    Locally advanced lymphoepithelial carcinoma of the larynx/hypopharynx: A case report.
    Oral Oncol. 2021;118:105373.
    PubMed     Abstract available


  417. TURNER MT, Stokes WA, Stokes CM, Hassid S, et al
    Airway and bleeding complications of transoral robotic supraglottic laryngectomy (TORS-SGL): A systematic review and meta-analysis.
    Oral Oncol. 2021;118:105301.
    PubMed    


  418. MCDOWELL L, Gough K, King M, Corry J, et al
    Patient-reported quality of life and symptom burden measures in human papillomavirus associated oropharyngeal cancer - A review of the literature and PRO methodology.
    Oral Oncol. 2021;118:105309.
    PubMed     Abstract available


  419. DHEERAJ K, Kumar R, Pinnaka LB
    6 "I" for endoscopic surgical management of early glottic squamous cell carcinomas.
    Oral Oncol. 2021;118:105308.
    PubMed    


    June 2021
  420. DAHLSTROM KR, Anderson KS, Guo M, Kwon MC, et al
    Screening for HPV-related oropharyngeal, anal, and penile cancers in middle-aged men: Initial report from the HOUSTON clinical trial.
    Oral Oncol. 2021;120:105397.
    PubMed     Abstract available


  421. JIANG WN, Olson R
    Transoral surgery may be less cost effective than radiotherapy: In response to: Comparative cost analysis between definitive radiotherapy and transoral surgery for oropharyngeal squamous cell carcinoma: A SEER-medicare analysis.
    Oral Oncol. 2021;117:105178.
    PubMed    


  422. PARIKH AS, Kang SY
    Variation in elective treatment of the contralateral neck in oropharyngeal cancer.
    Oral Oncol. 2021;117:105186.
    PubMed    


  423. COMBES JD, Voisin N, Perie S, Malard O, et al
    History of tonsillectomy and risk of oropharyngeal cancer.
    Oral Oncol. 2021;117:105302.
    PubMed     Abstract available


  424. JANSEN F, Coupe VMH, Eerenstein SEJ, Cnossen IC, et al
    Cost-utility and cost-effectiveness of a guided self-help head and neck exercise program for patients treated with total laryngectomy: Results of a multi-center randomized controlled trial.
    Oral Oncol. 2021;117:105306.
    PubMed     Abstract available


  425. PATEL MR, Ottenstein L, Ryan M, Farrell A, et al
    TORS elective lingual tonsillectomy has less acute morbidity than therapeutic base of tongue TORS.
    Oral Oncol. 2021;117:105294.
    PubMed     Abstract available


    May 2021
  426. COSTANTINO A, De Virgilio A, Spriano G
    Is the current oropharyngeal cancer T classification adequate in the era of HPV and transoral robotic surgery?
    Oral Oncol. 2021 May 25:105359. doi: 10.1016/j.oraloncology.2021.105359.
    PubMed    


  427. ZHOU L
    Concerns about human papillomavirus-associated oropharyngeal cancer detection methods.
    Oral Oncol. 2021;116:105143.
    PubMed    


  428. LI R, Wang Q, Yan L, Zhu Y, et al
    Radiotherapy versus partial laryngectomy in the management of early glottic cancer with anterior commissure involvement: A propensity score matched study with 256 patients.
    Oral Oncol. 2021;116:105230.
    PubMed     Abstract available


    April 2021
  429. YVER CM, Shimunov D, Weinstein GS, Rajasekaran K, et al
    Oncologic and survival outcomes for resectable locally-advanced HPV-related oropharyngeal cancer treated with transoral robotic surgery.
    Oral Oncol. 2021;118:105307.
    PubMed     Abstract available


  430. RAJASEKARAN K, Carey RM, Lin X, Seckar TD, et al
    The microbiome of HPV-positive tonsil squamous cell carcinoma and neck metastasis.
    Oral Oncol. 2021;117:105305.
    PubMed     Abstract available


  431. KREINBRINK PJ, Li J, Parajuli S, Wise-Draper TM, et al
    Pre-treatment absolute lymphocyte count predicts for improved survival in human papillomavirus (HPV)-driven oropharyngeal squamous cell carcinoma.
    Oral Oncol. 2021;116:105245.
    PubMed     Abstract available


  432. DHAKAL R, Moeller BJ, Prabhu RS, Frenkel CH, et al
    Pattern of distant metastasis in oropharyngeal carcinoma - Do they differ by HPV status?
    Oral Oncol. 2021 Apr 18:105286. doi: 10.1016/j.oraloncology.2021.105286.
    PubMed    


  433. PRICE JM, West CM, Mistry HB, Betts G, et al
    Improved survival prediction for oropharyngeal cancer beyond TNMv8.
    Oral Oncol. 2021;115:105140.
    PubMed     Abstract available


    March 2021
  434. DE ALMEIDA JR, Seungyeon Kim V, O'Sullivan B, Goldstein DP, et al
    Comparing unilateral vs. bilateral neck management in lateralized oropharyngeal cancer between surgical and radiation oncologists: An international practice pattern survey.
    Oral Oncol. 2021;114:105165.
    PubMed     Abstract available


  435. FERRARI M, Migliorati S, Tomasoni M, Crisafulli V, et al
    Sinonasal cancer encroaching the orbit: Ablation or preservation?
    Oral Oncol. 2021;114:105185.
    PubMed     Abstract available


  436. YANG K, Ahn YC, Nam H, Hong SD, et al
    Clinical features of post-radiation nasopharyngeal necrosis and their outcomes following surgical intervention in nasopharyngeal cancer patients.
    Oral Oncol. 2021;114:105180.
    PubMed     Abstract available


  437. HENG Y, Zhang D, Zhou L, Zhang M, et al
    Assessment and treatment strategies for occult contralateral lymph node metastasis in hypopharyngeal squamous cell carcinoma patients with ipsilateral node-positive necks.
    Oral Oncol. 2021;114:105183.
    PubMed     Abstract available


  438. CUI J, Wang D, Nie D, Liu W, et al
    Difference in tumor mutation burden between squamous cell carcinoma in the oral cavity and larynx.
    Oral Oncol. 2021;114:105142.
    PubMed     Abstract available


  439. OPPELT P, Ley JC, Worden F, Palka K, et al
    Palbociclib and cetuximab in cetuximab-resistant human papillomavirus-related oropharynx squamous-cell carcinoma: A multicenter phase 2 trial.
    Oral Oncol. 2021;114:105164.
    PubMed     Abstract available


  440. GOOSMANN M, Chang S, Craig J
    Treating sinonasal crusting and infection after palatal and sinonasal cancer resection with topical antibiotic irrigations.
    Oral Oncol. 2021;114:105077.
    PubMed    


    February 2021
  441. FADEN DL, O'Boyle CJ, Lin DT, Deschler DG, et al
    Prospective assessment of multiple HPV-positive oropharyngeal squamous cell carcinomas.
    Oral Oncol. 2021 Feb 15:105212. doi: 10.1016/j.oraloncology.2021.105212.
    PubMed    


  442. LEE SJ, Kim YS, Kay CS, Kim M, et al
    The effect of adjuvant chemotherapy and early tumor regression on the outcome of nasopharyngeal cancer patients treated with concurrent chemoradiotherapy.
    Oral Oncol. 2021;113:105130.
    PubMed     Abstract available


  443. CARNEVALE C, Ortiz-Gonzalez I, Ortiz-Gonzalez A, Bodi-Blanes L, et al
    Early T1-T2 stage p16+ oropharyngeal tumours. Role of upfront transoral robotic surgery in de-escalation treatment strategies. A review of the current literature.
    Oral Oncol. 2021;113:105111.
    PubMed     Abstract available


  444. HEFT NEAL ME, Gao RW, Brennan JR, Haring CT, et al
    Functional outcomes and tracheostomy dependence following salvage oropharyngeal surgery.
    Oral Oncol. 2021;113:105034.
    PubMed    


    January 2021
  445. PILAR A, Yu E, Su J, O'Sullivan B, et al
    Prognostic value of clinical and radiologic extranodal extension and their role in the 8th edition TNM cN classification for HPV-negative oropharyngeal carcinoma.
    Oral Oncol. 2021;114:105167.
    PubMed     Abstract available


  446. BHATTASALI O, Torres FA, Kang HK, Thompson LDR, et al
    Prognostic impact of retropharyngeal lymphadenopathy in early-stage HPV-associated oropharyngeal cancer: Implications for staging optimization.
    Oral Oncol. 2021;114:105147.
    PubMed    


    December 2020
  447. CHRISTOPHERSON KM, Moreno AC, Elgohari B, Gross N, et al
    Outcomes after salvage for HPV-positive recurrent oropharyngeal cancer treated with primary radiation.
    Oral Oncol. 2020;113:105125.
    PubMed     Abstract available


    September 2020
  448. MARTIN M, Sautois B
    Early onset of head and neck squamous-cell carcinoma and fatal toxicity with concurrent chemoradiotherapy in a patient compound heterozygote for FANCA gene.
    Oral Oncol. 2020 Sep 1:104989. doi: 10.1016/j.oraloncology.2020.104989.
    PubMed    


    August 2020
  449. CHEN TC, Wu CT, Wang CP, Lou PJ, et al
    The differences of immunologic and TP53 mutant phenotypes between synchronous and metachronous head and neck cancer and esophageal cancer.
    Oral Oncol. 2020;111:104945.
    PubMed     Abstract available


  450. WANG J, Lian CL, Zheng H, Lin LE, et al
    Cognitive dysfunction in patients with nasopharyngeal carcinoma after induction chemotherapy.
    Oral Oncol. 2020;111:104921.
    PubMed     Abstract available


    July 2020
  451. ZENG YY, Xiang ZZ, He T, Liu F, et al
    The comparison of prognostic value of tumour volumetric regression ratio and RECIST 1.1 criteria after induction chemotherapy in locoregionally advanced nasopharyngeal carcinoma.
    Oral Oncol. 2020;111:104924.
    PubMed     Abstract available


  452. WANG Q, Xu G, Xia Y, Zuo J, et al
    Comparison of induction chemotherapy plus concurrent chemoradiotherapy and induction chemotherapy plus radiotherapy in locally advanced nasopharyngeal carcinoma.
    Oral Oncol. 2020;111:104925.
    PubMed     Abstract available


  453. LI W, Lu H, Liu J, Liu Q, et al
    A novel nomogram to predict survival in patients with recurrent nasopharyngeal carcinoma after salvage endoscopic surgery.
    Oral Oncol. 2020;111:104922.
    PubMed     Abstract available


  454. HSU AC, Kokot NC, Eisenberg BL, Thomas JS, et al
    Complete response with talimogene laherparepvec in recurrent melanoma of the ear: A case report.
    Oral Oncol. 2020 Jul 11:104899. doi: 10.1016/j.oraloncology.2020.104899.
    PubMed     Abstract available


  455. MATOS LL, Pinheiro RA, Kowalski LP
    Depth of invasion applied to oropharynx does not improve prognosis discrimination according to AJCC stage groups for oral cancer.
    Oral Oncol. 2020 Jul 9:104890. doi: 10.1016/j.oraloncology.2020.104890.
    PubMed    


Thank you for your interest in scientific medicine.


AMEDEO Otorhinolaryngology is free of charge.